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ABSTRACT 
 
LEAH JILL SIRKUS MCGRATH: Influenza vaccine effectiveness among patients 
on hemodialysis: methods to control the healthy-user bias 
(Under the direction of M. Alan Brookhart) 
 
Background: Patients with end-stage renal disease (ESRD) are at 
increased risk for several preventable infections.  Although vaccines have been 
recommended for people with ESRD for many years, little is known about the 
level of vaccine effectiveness (VE) in preventing clinical health outcomes in this 
population. Observational studies of VE are challenging, however, because 
vaccinated persons may be healthier than unvaccinated persons. This 
dissertation aims to estimate influenza vaccine effectiveness among patients on 
hemodialysis using novel ways to control for bias. 
Methods: Using Medicare claims from patients on hemodialysis, a natural 
experiment was created by using year-to-year variation in the match of the 
influenza vaccine to the circulating virus. VE for influenza-like illness, 
influenza/pneumonia hospitalization, and mortality was estimated by comparing 
matched (1998, 1999, 2001) and mismatched (1997) years among vaccinated 
patients. An alternate method identified time-varying predictors of vaccination 
status and used these variables to control for time-varying confounding using a 
marginal structural model. 
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Results: Conventional estimates comparing vaccinated patients with 
unvaccinated patients suggested a large protective effect – influenza vaccine 
reduced mortality by 30%. The pooled VE estimate from the natural experiment 
of comparing matched seasons to a placebo was 0% (95% CI: -3,2%) for 
influenza-like illness, 2% (95% CI: -2,5%) for hospitalization, and 0% (95% CI: -
3,3%) for death. Hospitalization and skilled nursing care were highly associated 
with not being vaccinated, suggesting that these variables could be used to 
control for the healthy-user bias. The marginal structural model remained biased 
even after accounting for time-varying confounding, which likely resulted in 
exaggeration of the protective effect of the vaccine. 
Conclusions: Strong confounding bias is present when estimating 
influenza vaccine effectiveness. Controlling for bias using a natural experiment 
resulted in estimates of VE for all outcomes that were close to the null. This 
suggests that the current influenza vaccine strategy may have a smaller effect on 
morbidity and mortality in the ESRD population than previously thought. Alternate 
strategies (high dose vaccine, intradermal vaccine, and adjuvanted vaccines) 
should be investigated to achieve better health outcomes.  
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I. INTRODUCTION 
 
End-stage renal disease (ESRD) is the final stage of kidney disease 
where kidney function has decreased to less than 15% of normal and patients 
require a kidney transplant or dialysis to survive. Patients with ESRD are likely to 
have comorbidities, such as diabetes and hypertension, and are prone to 
contracting infections. Infection is one of the main causes of morbidity and 
mortality among patients with ESRD. It is the third leading cause of death, and 
infection-related hospitalizations have increased 43% since 1993.1   Vaccinations 
provide a simple, inexpensive way to protect these high-risk patients from 
infections such as influenza, pneumococcal pneumonia, and Hepatitis B. 
Although vaccines have been recommended for people with chronic renal 
disease for many years,2 little is known about the characteristics of patients who 
are vaccinated and the level of vaccine effectiveness in this population. One 
recent study investigating usage of influenza vaccine among ESRD patients 
reported less than 50% vaccination rates for both seasons between 1997-99.3  
Influenza vaccines are recommended by the Advisory Committee on 
Immunization Practices (ACIP) for people with chronic renal disease; however, 
there are few studies in this population that investigate the effects of this vaccine 
in relation to health outcomes. Most vaccine effectiveness studies have 
considered only the elderly. There has been only one randomized control trial 
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among the elderly population, which showed that the vaccine reduced lab-
confirmed influenza by 50%.4 It has proven difficult to accurately estimate the 
effectiveness of flu vaccine among the elderly population in non-experimental 
studies due to severe confounding by functional status5 and the “healthy-user 
effect”6 that is associated with receiving the vaccine. Although several high-
profile studies have suggested that the influenza vaccine may reduce all-cause 
mortality by as much as 50%,7-9 more recent studies have suggested that these 
estimates are due to confounding and the true effect may be small to 
negligible.5,10-13 Studies to better elucidate the effects of selection bias as well as 
the effectiveness of vaccines among the ESRD population are needed. 
The United States Renal Data System (USRDS) is a population-based, 
national system that collects information on all patients with ESRD in the United 
States. Because all ESRD patients are eligible for Medicare coverage, this 
system captures a substantial number of ESRD patient encounters, including 
medication usage, vaccinations, hospitalizations and deaths. Data have been 
collected from 1989-2007, thus the USRDS is an optimal data source for 
investigating trends in vaccine use over time, as well as how effective vaccines 
are in protecting against various health outcomes, such as hospitalization from 
pneumonia. The number of people with ESRD is expected to continue to grow, 
especially because of the growth of diabetes, which is a common cause of renal 
failure. Therefore, it is imperative to understand the current state of vaccine 
usage as well as the effectiveness of these vaccines in this population.  
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II. REVIEW OF THE LITERATURE 
 
  Overview of End-Stage Renal Disease A.
 
Description and epidemiology of ESRD 
 
End-stage renal disease (ESRD) is the final stage of kidney disease 
where kidney function has decreased to less than 15% of normal and patients 
require a kidney transplant or dialysis to survive. The kidneys can no longer 
adequately eliminate nitrogenous waste or fluid and fail to perform other 
biological processes including regulating pH. 
In 2009, there were more than 570,000 patients with ESRD in the U.S.1 
With the rising prevalence of diabetes and hypertension, this number is expected 
to increase to 774,386 by 2020. The prevalent population has been steadily 
increasing by ~2% each year since 2003. The incidence of ESRD has been rising 
since the 1980s, and although the rate dropped slightly in 2007 and 2008, it 
increased to 355 cases per million population (adjusted for age, gender, and 
race).1 Table 1 shows that elderly people aged 75 years and older, and African 
Americans have the highest rates of ESRD.  In fact, the incidence rate of ESRD 
among African Americans was 3.5 times the rate among Whites. In addition, 
ESRD affects people with Hispanic ethnicity disproportionally – 13% of all new 
cases of ESRD were among Hispanics, and the rate of ESRD among Hispanics 
is 1.5 times that of non-Hispanics.1   
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Table 1. Number and rate of cases of ESRD by age, race and ethnicity in 
20091  
 Incidence Prevalence 
 Number Rate* per 
million 
Number Rate* per 
million 
Overall 113,908 355 571,414 1,738 
Age     
  20-44 13,894 131 100,031 924  
  45-64 43,646 610 256,803 3,433 
  65-74 26,459 1,407 116,607 6,066 
  75+ 28,595 1,762 90,233 5,545 
Race     
  White 75,077 277 347,268 1,279 
  African American 32,116 976 180,685 5,284 
  Native American 1,404 522 7,682 2,735 
Ethnicity     
  Hispanic 14,766 501 87,866 2,538 
  Non-Hispanic 99,142 345 483,548 1,685 
*Adjusted to 2005 population cohort. 
 
Rates of ESRD vary substantially by geography. Generally, both incident 
and prevalent rates of ESRD are highest in the south and southwestern regions 
of the U.S. However, the oldest patients with incident ESRD are found in the 
upper Midwest, the Northeast and Florida. In addition, the highest rate for Whites 
and African Americans is in Pittsburg, Pennsylvania and for Hispanics is in 
Cincinnati, Ohio.2 
Patients with ESRD are very ill and mortality is high among this 
population. In 2009, the mortality rate for all ESRD patients was 148.3 per 1,000 
patient years and approximately 16% of prevalent cases of ESRD died. Mortality 
rates for patients on dialysis who are 65 years or older are ~6.5 times higher than 
the general population.1 The five-year survival for patients on dialysis is 34%; 
however, elderly ESRD patients have lower survival–the five-year survival for 
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patients aged 65 to 74 years is 26% and 13% for those aged 75 and older.1 
Mortality is high during the first year of dialysis; specifically, months two and 
three after initiation of dialysis have the highest mortality rates.3  
The cost of care of the ESRD patient population is substantial. In 2009, 
the cost of those covered through Medicare (~83% of all ESRD patients) was $29 
billion, which was 6.7% of the total Medicare budget (not including Part D). This 
cost increased 3.1% from 2008. Hemodialysis accounted for ~86% of the cost of 
ESRD care. The per person per year cost of care for ESRD was $82,000.1 Costs 
tend to be highest in the first year after initiating dialysis – due to high rates of 
hospitalization during initiation – and averaged $113,000 among older ESRD 
initiators.4 
Causes of ESRD 
The three most common causes of ESRD are diabetes, hypertension and 
glomerulonephritis. The mechanisms of kidney damage between these three 
causes frequently overlap, and often a patient will have both diabetes and 
hypertension, which can accelerate the process.  
Diabetes is the most common cause of ESRD. Approximately 30% of 
people with Type 1 diabetes and 25 to 40% of Type 2 diabetics develop ESRD,5 
although the disease generally does not appear until decades after the initial 
diabetes diagnosis. It is thought that hyperfiltration and a simultaneous increase 
in the glomerular filtration rate causes the initial damage to kidney capillaries, 
which eventually leads to loss of nephrons.5 In addition, complexes called 
advanced glycosylated end products (AGEs) may also contribute to kidney 
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damage. AGEs occur when excess glucose is bonded to red blood cells.6 These 
complexes can be deposited within the capillaries in the kidney, contributing to 
increased pressure and subsequent increase in glomerular filtration rate.    
Hypertension can also induce damage to the kidneys. High blood pressure 
is one of the leading predictors of development of ESRD.7 Hypertension can lead 
to higher pressure in the kidneys, which results in changes to the structure of the 
kidney capillaries and an ultimate loss in nephrons in similar ways as described 
earlier. It is thought that the renin-angiotensin system is also disrupted, further 
causing changes to blood pressure.8,9  
Glomerulonephritis is the third leading cause of ESRD, and is a term that 
encompasses many diseases that are characterized by inflammation of 
glomerular capillaries, and development of subsequent signs of nephritic 
syndrome including hematuria and proteinuria.10  In some cases, infection is the 
causative agent that triggers an auto-immune response, leading to renal 
damage. Other diseases, such as lupus, are chronic autoimmune diseases, 
which can cause similar damage over time.  These generally have an acute 
phase of glomerular damage, characterized by deposits of immune-complexes in 
the glomerular capillaries, leading to an eventual loss of nephrons.10 
Diabetes has been increasing as the primary cause of ESRD. In 2007, 
44% of new cases listed diabetes as the cause, whereas 28% were due to 
hypertension (Table 2). Incidence of ESRD due to diabetes has been increasing 
among younger minorities, although it seems to be stable among older 
populations and Whites.2  
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Table 2. Number and rate of ESRD cases by top causes in 20091 
 Incident ESRD Prevalent ESRD 
Cause of ESRD Number  Rate* per million Number Rate* per million 
Diabetes 50,970 154 215,245 647 
Hypertension 32,688 101 140,498 429 
Glomerulonephritis 7,612 24 84,883 263 
*Adjusted for age, gender, and race 
 
 
Dialysis 
Dialysis is the mechanical process by which the blood of an ESRD patient 
is cleaned of excess water, minerals and other products of metabolism. There 
are two types of dialysis: hemodialysis and peritoneal dialysis. Here we restrict 
our discussion to hemodialysis. The process of hemodialysis begins with a 
patient’s blood flowing through tubes into a cylindrical structure called the 
dialyzer while a premixed solution called the dialysate flows into the dialyzer in 
the opposite or countercurrent direction. A semi-permeable membrane 
composed of synthetic material separates the blood and dialysate compartments, 
but allows for the diffusion of solutes and the movement of water.  After the blood 
has passed through the dialyzer, it is returned to the patient through a separate 
tube. Patients undergoing hemodialysis generally must attend dialysis clinics 
three times a week. A small fraction of patients will attend only twice a week, if 
they have a higher level of kidney function. Hemodialysis sessions last 
approximately three to four hours.   
There are several types of facilities that administer hemodialysis to ESRD 
patients. The facilities are generally divided into for-profit and non-profit 
categories. The two largest for-profit providers are Fresenius and DaVita, treating 
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more than 200,000 patients combined. In addition, there are a variety of smaller 
dialysis organizations and hospital-based dialysis units that are other options for 
patients; however these facilities generally operate on a regional basis. 
Infectious complications 
Infection is the third leading cause of death (behind cardiovascular and 
“other” causes) and the second leading cause of hospitalization among ESRD 
patients. Infection-related hospitalizations have increased 43% since 1993.1 
Infection-related hospitalization is especially high within the first year of starting 
dialysis, and has increased nearly 100% since 1993.3  During 1996–2001, the 
one-year incidence proportion of infection-related hospitalization was 32% 
among adults initiating hemodialysis, and the three-year incidence was 53%.11 
The most common causes of infection-related hospitalization reported by the 
Hemodialysis Study – a randomized trial investigating the effects of dialysis dose 
- were infection from an unknown source including sepsis and bacteremia (35%), 
vascular access infection (23%) and respiratory infection (22%).12  
Impaired immune response in ESRD patients 
ESRD patients have impaired immune systems, which may complicate the 
response to vaccinations. It is thought that immune dysfunction is a result of two 
processes: (a) immune deficiency of both the adaptive and innate immune 
systems caused by uremic toxins and (b) immune activation resulting in chronic 
inflammation caused by the dialysis procedure.13 Although many pathways of the 
innate immune system are affected, here we will concentrate on the adaptive 
immune system, as these are the components of immunity that are involved in 
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attaining an adequate response to vaccinations, particularly B-cell production of 
antibodies. The predominant cells of the adaptive immune system that are 
directly depressed in ESRD patients are T-cells, although B-cells and antigen-
presenting cells (APCs) are also affected. T-cells control immunity by either 
directly attacking pathogens (killer T-cells) or by indirectly stimulating cells to 
produce antibodies (helper T-cells) and must be activated prior to differentiation. 
It is thought that overall T-cell activation is reduced in patients with ESRD.13 In 
addition, uremic toxins in the blood causes the function of APCs to decline, which 
thus impairs the ability of T-cells to differentiate.14  Patients with ESRD have 
fewer B-cells due to the indirect effect of having fewer helper T-cells and the 
direct effect of having a higher likelihood of B-cell apoptosis or cell-death.15  
Furthermore, the frequent, invasive process of hemodialysis has been shown to 
produce chronic inflammation.  Inflammatory cytokines are upregulated and push 
differentiation toward the Th1 pathway (leading to more killer T-cells), which 
results in even fewer B-cells.16 Finally, inflammation has been shown to be linked 
to atherosclerosis,17 which can lead to development of cardiovascular events and 
further impaired renal function, leading to further uremia and immune system 
dysfunction. 
Preventive Services 
Patients with ESRD generally have multiple health problems, some of 
which can be addressed with preventive care. There are several preventive care 
services that are recommended for patients with ESRD, including erythropoietin 
and intravenous iron for anemia management, phosphate binders and 
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intravenous vitamin D for common bone mineral metabolism disorders, diabetes 
and blood pressure management, and vaccinations.  
Anemia is a common problem in patients with ESRD. The National Kidney 
Foundation recommends that any person on dialysis achieve a hemoglobin level 
between 11.0-12.0 g/dl and no greater than 13.0 g/dl.18 In 2009, only 40% of 
patients were within this target.1 Anemia can be caused by iron deficiency, low 
levels of erythropoietin, or both.19 In patients with severe anemia, using 
erythropoietin-stimulating agents and intravenous iron supplementation raises 
hemoglobin levels, which has shown beneficial effects for health outcomes.20 
However, controversy persists about optimal hemoglobin targets as RCTs have 
demonstrated that full correction of anemia may increase mortality risk. 
Diabetes and hypertension are common causes of ESRD and 
management of these diseases can help to slow the progression of kidney 
failure. Patients with diabetes can slow kidney damage with glycemic control 
through insulin or oral hypoglycemic medications.5 It is recommended that 
diabetic patients receive A1c tests, lipid tests, and eye exams periodically. 
However, only 17% of ESRD patients received all three tests in 2009.1 In 
addition, it has been shown that treatment with blood pressure medications that 
affect glomerular pressure, such as angiotensin-converting enzyme inhibitors 
decrease the rate of renal failure among chronic kidney disease patients, 
although multiple medications may be needed.7,9   
Vaccinations are another preventive service that can have significant 
impact on health and mortality, as infection is a common cause of illness in 
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patients with ESRD. Although this population has a weakened immune system, 
vaccinations generally produce an adequate immune response to protect against 
future infection21 and have been found to be cost-effective, especially in older 
adults with chronic illness.22,23 
The health status of patients with ESRD is complicated by multiple factors. 
These patients are usually taking many medications to manage their multiple 
disease conditions as well as undergoing dialysis. However; because these 
patients are in contact with the health care system several times per week, there 
are multiple opportunities to administer these additional preventive services. The 
combination of a high annual mortality rate and the nearly $24 billion in annual 
healthcare costs incurred by these patients represent a clinical and public health 
priority for the optimal management, including preventive care, of ESRD.  
 Vaccinations and the ESRD population B.
Vaccinations indicated for ESRD patients 
The ACIP24 recommends that all ESRD patients and patients with chronic 
kidney disease receive influenza, Hepatitis B, and pneumococcal vaccines. Other 
vaccines, such as Hepatitis A and tetanus/diphtheria/pertussis, can be 
administered on an as-needed basis. 
Trivalent, inactivated influenza vaccine (TIV) is indicated for yearly 
administration among ESRD patients. TIV is made by growing the virus in 
chicken eggs. Subsequently,  the virus is inactivated and purified into the vaccine 
form.25 TIV contains three strains of influenza: Type A (H1N1), Type A (H3N2), 
and Type B. In nature, the influenza virus is constantly changing through a 
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process called antigenic drift. Therefore, the strains included in the vaccine are 
updated on a yearly basis to better match the strains that are circulating in the 
community. The vaccine is most effective when administered at least 2 weeks 
prior, but no more than 4 months before exposure to influenza in the community. 
Because influenza peaks between December and March, the optimal time for 
vaccination is October and November.25 Vaccine is generally available as early 
as September. ESRD patients should not receive the live attenuated influenza 
vaccine due to their potential immunocompromised state.24 Although patients on 
dialysis have lower response rates to influenza vaccine compared with healthy 
adults, it has been shown that 46–87% of dialysis patients developed protective 
antibody titers after vaccination.21,26  
 Hepatitis B vaccine is a recombinant vaccine, where the gene for 
Hepatitis B surface antigen is inserted into yeast cells. The surface antigen gene 
is expressed by the yeast cells, and the resulting protein is purified to form the 
vaccine.25 It is recommended that all patients currently undergoing dialysis 
treatment receive a higher vaccine dose than is normally administered, as the 
immune response may not result in adequate antibody titers.24 Thus, the 
recommended schedule is 3 doses of 40 micrograms each, given at 0, 1, and 6 
months. In addition, antibody titers may wane faster among this population. 
Generally, patients with an initial immune response will lose adequate protection 
after one year following immunization.27  Antibody titers can be checked 
periodically to monitor the level of protection and to assess the need for booster 
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doses. Booster doses should be provided when antibody levels drop below 10 
mIU/mL.25  
It is recommended that people who are at increased risk of pneumococcal 
infection, including patients with ESRD, receive the 23-valent pneumococcal 
polysaccharide vaccine. The vaccine contains 23 different strains of 
Streptococcus pneumoniae, including the six serotypes that cause the majority of 
invasive disease.28  Capsular polysaccharide antigens from each bacterial 
serotype are purified to make the vaccine.25 Pneumococcal vaccine is typically 
administered only once, but one booster dose can be given to ESRD patients 
after 5 years. People with chronic kidney disease generally produce an adequate 
response to immunization, however, the antibody level wanes faster than in 
healthy subjects. One study showed that 71% of hemodialysis patients produced 
a protective antibody level, but only 43% maintained that level at one year post-
vaccination.29 Generally, patients on dialysis have lower antibody titers than 
those with chronic kidney disease who are not on dialysis.30   
 
Table 3. Recommended vaccinations for ESRD patients 
Vaccine Dosage 
schedule 
Amount Route 
Influenza Yearly 0.50 mL Intramuscular 
Hepatitis B 0, 1, 6 months 
+ booster if 
needed 
40 μg Intramuscular 
Pneumococcal Once + 1 
booster at >5 
years 
0.50 mL Intramuscular 
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Utilization of vaccines among the ESRD population 
The utilization of vaccines by patients with ESRD is low, even though 
Medicare covers the entire cost of the vaccines. Reported Medicare coverage 
rates are expected to be lower than the true utilization rate in the population 
because people who are covered with private insurance or who pay out of pocket 
(~17% of ESRD patients1) are not captured in coverage rates. However, 
estimation of relative trends over time should remain unbiased. Examination of 
these trends shows an increase in uptake for influenza, pneumococcal and 
Hepatitis B vaccines over the last ten years.1  
Influenza vaccination rates remain much lower than the Healthy People 
2010 goal of 90% coverage, even after increased educational campaigns. In 
2009, only 64.3% of ESRD patients were reported to be vaccinated for influenza. 
Hemodialysis patients had a slightly higher vaccination rate of  69.3%1, which is 
a 42% increase compared to the epidemic year of 1998–1999 where the 
immunization rate among hemodialysis patients was 48.8%.31  
Overall pneumococcal vaccination rates remain low. Among patients with 
ESRD, revaccination is recommended once after 5 years.28 Because patients 
could have been vaccinated prior to initiating dialysis, it is difficult to measure the 
absolute vaccination rate. However, trends over time suggest that rates of 
vaccination remained stable at approximately 13% until 2001, when the rates 
began increasing dramatically.3 Although rates began to plateau in 2005, by 
2009 the vaccination rate had doubled to 26%.1 Hemodialysis patients have a 
slightly higher vaccination rate of 30%.    
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Hepatitis B vaccine has historically been an underused vaccine in the 
ESRD population and continues to be underutilized even though ESRD patients 
are at high risk of contracting Hepatitis B. In 2009, only 22.1% of patients 
received one Hepatitis B vaccine, meaning the percentage of patients receiving 
the required three doses was even lower.1 Although the usage rate is low, not all 
prevalent ESRD patients may currently need a vaccine as evidenced by antibody 
testing. The rate among new dialysis initiators is unknown and may be a better 
indicator of coverage. Regardless of the method of calculation, the rates are 
lower than they should be. The low usage rates of Hepatitis B vaccine are most 
likely due to the sub-optimal antibody response rates that are achieved with this 
vaccine in this population. Investigations are currently ongoing into using different 
routes of administration of vaccine32 and various adjuvants that may increase 
response rates and duration of protection.33    
 Measuring influenza vaccine effectiveness C.
Methodological considerations in measuring influenza vaccine 
effectiveness 
 
Vaccine effectiveness (VE) is generally measured by comparing outcomes 
in people who are vaccinated versus those who are not vaccinated. Effectiveness 
is expressed as a percentage and is calculated as: VE = 1 - a measure of relative 
risk (i.e., risk ratio, odds ratio, hazard ratio).34 Past studies of influenza vaccine 
effectiveness have focused on seniors older than 65 years, as this population is 
at higher risk of death from influenza, and the true effect of the vaccine is 
uncertain and likely lower than in healthy adults due to immune senescence. 
Influenza VE studies must rely on observational study designs, as randomized 
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control trials would be unethical to implement. Because vaccination is a 
preventive service, those that are vaccinated may constitute a much different 
population then those that are unvaccinated, leading to substantial confounding. 
Thus, there is significant controversy on the role of biases in influenza VE 
studies.  
The bias that occurs when users of a preventive medication are a different 
population than nonusers is called the healthy-user bias.  This bias is apparent 
when the users also undertake other healthy behaviors. This confounds the drug-
disease relationship, making the drug or vaccine under study look better than it 
actually is.35 The healthy-user bias has been illustrated in studies of hormone 
replacement therapy and cardiovascular disease36 and with statin therapy and 
several disease outcomes.37,38  Conversely, it has been suggested in studies of 
influenza vaccine effectiveness in the elderly–that patients who are not 
vaccinated have a lower functional status.39 Often it is difficult to identify what 
these “healthy behaviors” are and even more difficult to measure them in 
administrative claims data. However, to obtain unbiased effect estimates it is 
critical to adjust for this bias in the analysis.  
There are several other factors to consider when estimating influenza VE. 
First is the seasonality of influenza. Although influenza generally peaks between 
December and March, the virus can begin circulating as early as November and 
can last until May. Studies use different methods to delineate the start and end of 
the flu season, as well as the start of the “pre-flu” season – the period after 
vaccine has been distributed but before the start of circulating flu. Health 
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maintenance organization (HMO)-based studies often obtain a clearer picture of 
these dates by using laboratory results from testing isolates in their own patient 
population. Studies using national data sources, including administrative claims 
databases, usually use CDC estimates of national or regional estimates of 
influenza circulation. Although this method may induce some exposure 
misclassification, several studies have compared national estimates to local 
estimates and found little difference in dates.40,41 Regional CDC estimates of 
start and end dates generally do not vary substantially from national estimates.     
The degree to which the vaccine matches the circulating strain is another 
factor to consider. Each year, influenza vaccine includes three influenza strains 
(A/H1N1, A/H3N2, B), which are chosen months in advance of the beginning of 
the season and are based on the strains circulating in the southern hemisphere. 
Sometimes the virus that predominates in a season undergoes significant drift, 
and thus the vaccine does not provide immunity to that strain. Only seasons with 
a well-matched vaccine are expected to be effective in preventing influenza-
related outcomes.  
Some influenza seasons are more severe than others (i.e. there are more 
deaths/hospitalizations due to pneumonia/influenza). It has been shown that 
seasons that are predominated by A/H3N2 are generally more severe than 
seasons with circulating A/H1N1 or B strains (this excludes the recent situation of 
influenza shift, where an H1N1 strain re-assorted to produce a completely new 
strain).42 Vaccine effectiveness would be expected to be greater in more severe 
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seasons because it is thought that the vaccine has the most effect on preventing 
severe disease.  
Finally, the specificity of the outcome studied will have an impact on the 
estimate of VE. Studies vary in the outcome that is used: outcomes include all-
cause mortality, influenza/pneumonia (I/P)-specific mortality, all-cause 
hospitalization, I/P hospitalization, cardiac hospitalization, and influenza-like 
illness. One would expect that as the specificity of the outcome decreases, the 
vaccine effectiveness would also decrease (for example, VE for all-cause 
mortality should be expected to be lower than VE for I/P hospitalization),43 
however this is not the case with traditional observational methods, due to 
suspected selection bias. 
Traditional methods to measure influenza vaccine effectiveness produce 
biased results 
 
Many studies have reported large vaccine effectiveness estimates for 
clinical health outcomes – some studies report up to a 50% reduction in all-cause 
mortality.44-52 These estimates seem to be effected by substantial bias, as only 
~5% of all wintertime, senior deaths are attributed to influenza.53 Furthermore, 
traditional studies generally report a larger effect for all-cause mortality than more 
specific outcomes such as I/P hospitalization, which is difficult to logically 
interpret, as one would expect smaller estimates for less specific outcomes. 
Nichol et al. used propensity score methods with logistic regression models to 
adjust for several suspected confounders, but reported a 48% VE for all-cause 
death, and a 27% VE for I/P hospitalization.54 Hak et al. used simple logistic 
regression, adjusting for comorbidities and reported a 50% VE for all-cause 
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death, and 48% for hospitalizations.55 Nordin et al. used similar methods and 
reported a reduction in all-cause death of between 35–61% and a reduction in 
hospitalizations of 18–24% depending on the season.49  
Methodological improvements in measuring influenza vaccine 
effectiveness 
 
Using the pre-influenza period as a negative control 
It is expected that VE during the “pre-influenza” period would be nearly 
zero, as influenza is rarely circulating (i.e., only sporadic cases may be seen), 
and thus the vaccine should not have any effect on health outcomes. Therefore, 
estimates during the pre-influenza period that are greater than zero, must be 
biased in some way. Several studies have used the pre-influenza period as a 
negative control, by implementing a model-building strategy using this time 
period to determine which variables adequately control the selection bias. These 
variables are subsequently included in their final VE model, which is calculated 
for the period during the influenza season.41,56,57  
Including variables to account for confounding by frailty and the healthy-user bias  
Jackson et al. have ascertained that functional status is a significant 
confounder in the relationship between influenza vaccine and all-cause mortality 
in seniors.39 The ability of elderly people to travel to a place to receive a vaccine 
may be severely diminished if the person has limited mobility. Functional status is 
generally assessed using medical record review and may include variables such 
as presence of dementia, ability to walk without assistance (cane, walker, etc.), 
requiring assistance to bathe, and living in a non-home setting such as an 
assisted living facility.  Patients with limited functional status were between 40–
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50% less likely to receive influenza vaccine and 2 to 5 times more likely to die 
than those with adequate functional status.39 Another cohort study using the 
General Practice Research Database used the number of repeat prescriptions in 
the preceding 12 months as a proxy for health status, which resulted in similar 
estimates of VE for respiratory disease hospitalization and death.58 This study, 
however, did not compare the estimates to the pre-influenza period to determine 
the amount of residual bias.  
 It is uncertain whether functional status or frailty may act as a confounder 
in the ESRD population. Because ESRD patients come into contact with health 
care facilities 2 to 3 times per week, the issue of functionally being able to go out 
to receive the vaccine may not an issue. However, patients who are very near 
death (i.e., severely functionally limited) may be less likely to be vaccinated. 
Thus, the association between functional status and vaccination may be different 
in the ESRD population as compared with the general, elderly population.  
Utilizing specific influenza seasons to determine effects of bias 
Influenza seasons have varying levels of vaccine match. Using this 
external information can also function to provide a negative control for 
determining bias in estimating VE. To investigate the effects of bias on VE 
estimates, using a season with poor vaccine match to the circulating strain, 
should result in no effect, or at best a very small effect. Thus, if the estimate of 
VE is large, it is most likely biased in some way. The 1997–1998 and 2003–2004 
seasons had very low levels of vaccine match. Therefore, utilizing these seasons 
would be best suited for investigating bias. Similarly, severity of the influenza 
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season is another issue to consider when pooling seasons to measure the effect 
of bias. One would expect more severe seasons to have higher levels of VE (i.e., 
if there is more virus circulating or a more virulent virus, the vaccine will have a 
higher likelihood of preventing serious illness). When trying to estimate the upper 
bound of VE, one should use severe seasons with high vaccine match. 
Summary of vaccine effectiveness estimates using improved methods 
Several studies have implemented the previously mentioned 
methodological improvements in elderly populations. Table 4 compares 
estimates of VE using traditional methods with studies that incorporated 
improvements to study design. Studies that use traditional adjustment methods 
result in larger estimates of VE than methods used to control selection bias. 
Thus, additional methods are needed to adequately control the healthy-user bias 
that is inherent in influenza VE studies.  
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Table 4. Comparison of VE estimates for traditional vs. improved analyses 
 Traditional Improved 
Population Methods 
Used 
VE: 
All-cause 
death 
(95% CI) 
VE: 
I/P hosp. 
(95% CI) 
Methods Used VE:  
All-
cause 
death 
(95% CI)  
VE: 
I/P hosp. 
(95% CI) 
Elderly >64 
years 
Cox model/ 
propensity 
score
54
 
48%  
(45-50%) 
27% 
(23-32%) 
Conditional 
logistic/ 
functional 
status 
adjusted
39
 
 
29% 
(-6, 53%) 
 
    Poisson/ 
adjusted for 
prescriptions
58
 
 
21% 
(19-23%) 
21%  
(17-26%) 
 Adjusted 
logistic 
regression
55
 
50% 
(23-68%) 
48% 
(7-71%) 
 
Case-centered 
logistic 
regression
59
 
 
4.6% 
(1-8%) 
8.5% 
(3-13%) 
    Conditional 
logistic/Pre-flu 
period 
calibrated
41
 
 8%* 
(-10-23%) 
 Matched, 
conditional 
logistic
60
 
35-39% 27-30%    
       
 Meta-
analysis
61
 
50% 
(45-56%) 
33% 
(19-47%) 
   
       
Elderly  >64 
years with 
chronic lung 
disease 
Poisson/time-
varying 
exposure
48
 
70% 
(57-79%) 
52% 
(18-72%) 
 
   
*VE estimate for community-acquired pneumonia 
 
Using the ESRD population to measure vaccine effectiveness 
There are many advantages to investigating methods for assessing 
influenza VE among ESRD patients. First, all patients with ESRD are eligible for 
Medicare and are captured in the USRDS. Although some patients do not have 
Medicare as a primary payer (and thus more detailed information is not 
captured), this proportion is small. Therefore, using the USRDS population 
represents the majority of the ESRD population. Second, patients with ESRD 
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come into contact with health care facilities often, up to 2 to 3 times per week. 
Thus, there are ample opportunities for vaccination. Although patients could 
receive influenza vaccine from outside facilities (and thus not be reported through 
Medicare), we think that this situation is most likely infrequent. Third, claims data 
are reported monthly, thus we have ample time points to assess vaccination 
status, hospitalizations, and other variables that may be useful in assessing 
proximity to death/functional status such as administration of preventive 
medications. Finally, there are many parallels between patients with ESRD and 
the general elderly population. Both have impaired immune systems and the true 
effectiveness of influenza vaccine is controversial in both populations. Methods 
developed using data on ESRD patients may be transferable to investigation of 
the general elderly population. 
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III. STATEMENT OF SPECIFIC AIMS 
 
Specific Aim One 
 
Aim: Assessing influenza vaccine effectiveness among patients on 
hemodialysis by comparing vaccinated patients in a “high-match” year to 
vaccinated patients in a “low-match” year. 
Hypothesis: Patients undergoing hemodialysis who receive the influenza 
vaccine in a high-match year will have a lower hazard of influenza-like illness and 
hospitalization due to influenza/pneumonia and a lower hazard of all-cause death 
than patients who receive the influenza vaccine in a low–match year, in seasons 
with comparable severity.  
Rationale: We expect that there will be large differences in health status 
between patients who are vaccinated and those who are not. Therefore, 
comparing vaccinated with unvaccinated people may lead to a biased estimate of 
vaccine effectiveness. Thus, comparing only those who are vaccinated in 
different seasons with similar severity should reduce the healthy-user selection 
bias and allow for a better estimate of vaccine effectiveness.   
Specific Aim Two 
 
Aim: Assessing the relation of time-fixed and time-varying predictors, such as 
hospitalization and skilled nursing care, with the receipt of influenza vaccine to 
characterize the healthy-user bias in a population on hemodialysis. 
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Hypothesis: Patients undergoing hemodialysis and who have been recently 
hospitalized or received skilled nursing care are less likely to be vaccinated. 
Vaccinated patients are more likely to be healthier, younger, more adherent to 
their dialysis schedule, and more likely to take other preventive medications than 
those who are not vaccinated.   
Rationale: Patients on hemodialysis who are hospitalized are likely to be 
sicker than those who have not been hospitalized, and physicians may be less 
likely to vaccinate if a patient has serious health problems. In the elderly 
population, it has been shown that those who are healthier are more likely to be 
vaccinated. It is not known whether this association will also be observed in the 
population undergoing hemodialysis. Because these patients have frequent 
contact (2–3 times per week) with health care facilities, it would be expected that 
they would have higher vaccination rates than the general elderly population. 
Knowledge of current vaccination patterns can also inform the development of 
healthcare quality improvement interventions designed to increase the utilization 
of preventive healthcare services. 
Specific Aim Three 
 
Aim: Assessing influenza vaccine effectiveness on mortality among patients 
on hemodialysis by developing a marginal-structural model to account for time-
varying confounding by health status. 
Hypothesis: It is anticipated that unadjusted analyses will attribute an 
exaggerated effect of vaccination on mortality risk.  When important time-varying 
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measures of health status such as hospitalizations are adjusted for, we 
hypothesize that attenuated estimates of vaccine effectiveness will result. 
Rationale: Vaccination status is a time-varying exposure, and any variable 
that vaccination affects and is also a confounder of subsequent vaccination and 
death cannot be modeled using traditional regression. This is because the time-
varying confounders – such as hospitalization and skilled nursing care – are also 
intermediate variables, and adjustment for these variables using regression will 
produce a biased estimate. Marginal structural models use inverse-probability-of-
treatment weights to create a pseudo-population where vaccination and death 
are unconfounded by time- varying confounders. Under certain assumptions, 
these methods can yield less biased estimates of vaccine effectiveness. 
 
 
IV. METHODS 
 
 Subject Identification A.
 
Study Population 
 
This study utilizes data on hemodialysis patients from the USRDS. The 
USRDS is a population-based, national system that collects information on all 
patients with ESRD in the United States. All persons that are diagnosed with 
ESRD and started on dialysis therapy are entered into the USRDS. The 
diagnosing physician is required to complete the End Stage Renal Disease 
Medical Evidence Report (CMS-2728), regardless of the insurance status of the 
patient. Basic information such as demographics, cause of kidney failure, and 
categories of comorbidity are included on this form. Although all patients with 
ESRD are eligible for Medicare coverage regardless of their age, some patients 
remain on private or HMO insurance or have a combination of insurance 
coverage.  More detailed information such as physician services, 
hospitalizations, and cause of death is captured through administrative claims 
submitted through Medicare. Non-hospitalization-related claims, including routine 
dialysis care and medication use (including vaccinations) are generally submitted 
on a monthly basis. Vaccinations are identified using Current Procedural 
Terminology (CPT) and Health Care Financing Administration Common 
Procedural Coding System (HCPCS) codes (see the following). This information 
37 
 
is collected only for those patients who are enrolled in Medicare as a primary 
payer, and those that are not enrolled in Medicare can be considered as missing 
data. In 2009, approximately 83% of ESRD patients were covered by Medicare 
as a primary payer.1 This study will be limited to Medicare patients who have 
been receiving dialysis for at least three months. This is the amount of time that 
is generally required to process the Medicare eligibility and enrollment forms.  
Collection of data 
 
The USRDS collects data primarily from the Centers for Medicare and 
Medicaid Services (CMS) Renal Beneficiary and Utilization System, which is 
supplemented from the Renal Networks’ Standard Information Management 
System.1 Claims data are sent from each ESRD network to CMS on a monthly 
basis. Almost all patients diagnosed with ESRD are captured in the system, as all 
providers are required to submit a Medical Evidence Report, regardless of 
insurance status. Each patient is assigned a unique patient identification number 
upon receipt of the form. The first service date is generally considered to be 
complete for all patients, while other data fields (such as comorbidities) on the 
form may not be of similar quality.  
Study Setting and Design 
 
This study incorporates a cohort study design. Eligible patients were 
enrolled prior to the start of influenza season each year, and the outcome –
ILI/hospitalization/mortality status for Aim 1, vaccination for Aim 2 and death for 
Aim 3 – was subsequently assessed. For Study Aims 1 and 3, each influenza 
season was divided into specific time periods: “a pre-influenza period” defined as 
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the time between the start of vaccine distribution (assumed to be September 1) 
and the start of the influenza season. The “influenza period” was defined using 
Centers for Disease Control and Prevention’s (CDC) national laboratory data on 
positive influenza isolates. The start date was defined as the midpoint of the first 
week with >10% of isolates submitted positive for influenza. We conducted a 
sensitivity analysis where the influenza season started when >5% of isolates 
were positive. The influenza season ends at distinct points, also characterized by 
CDC surveillance. However, we continued to follow patients for outcomes 
through August 31st of the following year. Figure 1 displays how the influenza 
season was broken into periods for analysis.   
Figure 1. 2001-2002 influenza season periods 
 
 
 
 
 
 
 
Identification of cohorts 
 
For each influenza season, a cohort of ESRD patients was identified. All 
adult patients (>17 years at first date of dialysis) on continuous hemodialysis with 
Medicare as their primary payer who initiated therapy prior to October 1 of the 
previous year and remained alive until September 1 of the current year (i.e., start 
of vaccine distribution) were eligible for that yearly cohort. Exposure was 
assessed starting on September 1 of each year and follow-up ended on the 
earliest date of outcome, death, transplant, or end of study (December 31 for Aim 
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2, August 31 for Aim 1 and 3). Claims from the USRDS that occurred between 
1997 to 2005 were utilized. There were approximately 900,000 patient years 
available (~100,000 patient years per year). Figure 2 depicts the time periods 
used to construct the 2000–2001 influenza season annual cohort.  
 
Table 5. Study eligibility requirements 
Variable Requirement 
  
Age 18 years and older 
Insurance status Medicare as primary payer 
Dialysis status Continuous hemodialysis 
Date of ESRD Prior to October 1 
  
 
 
Figure 2. Annual cohort for the 2000–2001 influenza season defined for  
Study Aim 3 
 
 
 
 
 
 
 
 Exposure and Outcome Definitions B.
 
Hospitalization and skilled nursing care exposures 
Study Aim 2 investigates hospitalization due to any cause and skilled 
nursing care as the exposures of interest. Inpatient hospitalization and skilled 
nursing facility admission and discharge dates were assessed using the Part A – 
Hospitalization Medicare claims. Both variables were coded as a count of the 
number of hospital or skilled nursing days the patient had in the prior 30 days. 
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The data were structured into a person-week format, thus these variables were 
updated each week.  
 
Vaccination (Aims 1 & 3 = exposure, Aim 2 = outcome) 
 
Vaccinations were identified by searching billing codes from Medicare Part 
B (physician) and Part A (hospital outpatient) claims files. Vaccinations are coded 
using CPT or HCPCS codes. We also included the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) procedure code, so we 
could capture vaccinations administered in the hospital. Table 6 displays the 
CPT, HCPCS, and ICD-9-CM procedure codes that were searched to identify 
any vaccinations.  
 
Table 6. CPT and HCPCS vaccination codes2 
Vaccination CPT HCPCS ICD-9 Procedure 
Influenza 90724 
90656 
90658 
90659 
90660 
G0008 
G8482 
99.52 
  
 
Influenza-like illness 
 
Inpatient and outpatient claims were examined and ICD-9-CM codes were 
searched for codes consistent with influenza-like illness (ILI), as in Lindsay, et al. 
(Table 7).3  
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  Table 7. ICD-9-CM codes used to define influenza-like illness3 
Description ICD-9-CM code 
Influenza 487, 487.0, 487.1, 487.8 
Upper respiratory infections 465 
Acute laryngitis and tracheitis 464 
Acute bronchitis and 
bronchiolitis 
466 
Bronchitis not specified 490 
Pulmonary collapse 518.0 
Acute respiratory failure 518.81 
Unspecified viral pneumonia 480.9 
Bronchopneumonia organism 
unspecified 
485 
Pneumonia organism 
unspecified 
486 
Secondary bacterial 
pneumonias: Klebsiella 
pneumonia, Haemophilus 
influenza, Streptococcus, 
Staphylococcus 
482.0, 482.2, 482.3, 482.4 
 
Influenza/pneumonia hospitalization outcome 
 
Discharge diagnoses for all hospitalizations were examined and ICD-9-CM 
codes were searched for influenza and pneumonia diagnoses. Codes 480.xx – 
487.xx were used for this outcome. Pneumonia diagnoses were included 
because pneumonia is often a secondary complication to influenza infections. In 
general, diagnosis codes for pneumonia in administrative claims databases have 
modest sensitivity, but good specificity.4,5 It has been shown that using outcome 
codes with high specificity will not bias the effect estimates of relative risk even 
when sensitivity is low.6  
Death 
 
Deaths are reported using CMS form 2746 – ESRD Death Notification. 
CMS requires all dialysis providers to submit this form within 30 days of a 
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patient’s death. Reporting of deaths is nearly complete – CMS estimates 99% of 
deaths are captured using this form.7  Data collected on this form include the 
date of death and the cause of death. Because cause of death may be difficult to 
ascertain, especially for deaths occurring in non-hospital settings, we used death 
from any cause as the outcome of interest in this analysis. 
 Covariate Definitions C.
 
All confounders were identified using the existing evidence base – 
including the investigative team’s knowledge and the published literature. The 
model form of all covariates is given in Table 8. For all categorical variables, the 
reference category was coded with a “0.” For the continuous variable age, more 
flexible functional forms (quadratic, restricted cubic spline) were investigated; 
however the simple linear form was deemed to be an adequate fit.  
The Centers for Medicare and Medicaid Services form 2827, the Medical 
Evidence Form, was used to ascertain age, race, gender, first service date with 
ESRD, and cause of kidney failure. The eight month window from January 1 to 
August 31 was searched for use of oxygen and the following comorbidities in 
both Part A and Part B claims as identified in Liu et al.8–atherosclerotic heart 
disease, congestive heart failure, cerebrovascular accident/transient ischemic 
attack, peripheral vascular disease, other cardiac, chronic obstructive pulmonary 
disease, gastrointestinal bleeding, liver disease, dysrhythmia, cancer, and 
diabetes. Comorbidities were modeled as individual dichotomous variables in the 
final models. Adherence to dialysis was calculated using the sum of the number 
of dialysis sessions over the eight month baseline period:  patients were 
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considered adherent if they had 95 sessions or more (assuming 12 dialysis 
sessions per month and allowing one less session due to the variable number of 
days per month).  Patients with no dialysis sessions over the eight–month period 
were dropped from the analysis. We also included the total number of hospital 
days each patient accumulated over the eight–month period. Use of mobility aids 
were ascertained by searching Part A and Part B claims for HCPCS equipment 
codes for wheelchairs, walkers, canes, and assisted bathroom equipment during 
the baseline period (Table 9). 
Table 8. Model form for all covariates 
Variable Coding 
 Age at September 1 Continuous, linear term 
Race 0 = White 
1 = African American 
2 = Other 
Sex 0 = Female 
1 = Male 
Cause of ESRD 0 = Diabetes 
1 = Hypertension 
2 = Glomerulonephritis  
3 = Cystic Kidney  
4 = Other 
Dialysis vintage (years since dialysis 
initiation) 
0 = 0 years 
1 = 1–2 years 
2 = 3–4 years 
3 = 5–9 years 
4 = 10+ years 
Comorbidities 0 = Comorbidity absent 
1 = Comorbidity present  
Adherence to dialysis therapy  0 = Non-adherent 
1 = Adherent 
Use of mobility aids 0 = None 
1= 1 mobility aid 
2 = 2+ mobility aids 
ESRD Network #1–18 Reference cell coding with Network 
18 as the referent 
Baseline hospital days Continuous, linear term 
Oxygen use 0 = No 
1 = Yes 
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Table 9. Codes used to define the use of mobility aids & oxygen use 
Mobility aid description HCPCS code 
Use of wheelchair E0950 – E1228, E1230, E1240 – 
E1298 
Use of walker/cane E0130, E0135, E0140, E0141, 
E0143, E0144, E0147, E0148, 
E0149, E0105, E0100 
Use of modified bathroom equipment E0240 – E0248 
Oxygen use E0430-E0435, E0439-E0444 
  
 Statistical Model D.
 
The hazard of each outcome among exposed patients versus unexposed 
patients was modeled using the Cox proportional hazards model9 with a time–
varying exposure. The Cox model is specified as: 
 
  ( | )     ( )    (∑   
 
     ), 
 
 
where  ( | ) is the hazard rate at time t for an individual with covariate pattern Z, 
and   ( ) is the baseline hazard rate. To calculate the hazard ratio (HR) 
comparing vaccinated versus non-vaccinated patients for example, the ratio of 
the hazard rates in each group is computed as:  
 ( | )    ( )    (∑   
 
     )
 ( |  )    ( )    (∑   
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where    includes all vaccinated and   
  includes those that were unvaccinated.  
Patients were considered to be censored upon death (for non-death outcomes), 
transplant, loss to follow-up, or end of study. For some analyses, patients could 
be included in multiple cohorts and thus have multiple outcomes; thus, a robust 
variance estimator was inspected that would account for the non-independence 
of the data. For all Cox models, Efron’s method for tied event times was used.10 
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 Methods pertaining to Specific Aim One E.
Exposure Measure 
 
The exposure measure was the degree that the vaccine matched the 
circulating strain during that influenza season.  We chose to analyze specific 
years based on the characteristics of each influenza season – years with similar 
influenza severity and close temporally to the mismatched season. In addition, 
years before it was common to pay out of pocket at grocery stores or pharmacies 
were used to limit exposure misclassification. A “high -match” year was 
considered exposed. This means that the majority of isolates tested during the 
season were strains that were included in the vaccine. The following seasons 
were considered “high-match” years that had similar levels of severity (i.e., H3N2 
strain predominated): 1998/99, 1999/00, and 2001/02. We excluded the 2000 
season to limit differences between seasons due to influenza severity; the 
predominate strain in the community in 2000 was a less severe strain 
(A/H1N1).11  A “low-match” year, 1997/98, was considered as unexposed. Most 
of the isolates in this season did not match the vaccine, and thus vaccine 
effectiveness would be anticipated to be low.  It has been documented that the 
1997–98 influenza vaccine (Wuhan variant) did not match the circulating strain 
(Sydney variant) 12 and outbreak investigations suggested that the vaccine 
provided limited protection.13 A randomized controlled trial confirmed that the 
inactivated vaccine did not prevent clinical outcomes during the 1997–98 season 
among healthy, working adults younger than 65 years – vaccinated patients had 
more influenza-like illnesses and upper respiratory tract infections than placebo 
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patients.14 Table 10 shows the characteristics of each season that was used in 
this analysis.  
Table 10. Description of selected influenza seasons12,15-18 
Season % I/P hospitalization 
(Proxy for severity) 
% Vaccine Match 
1997–1998 9.8 19 (mismatch) 
1998–1999 9.7 90 
1999–2000 11.2 97 
2001–2002 9.1 100 
 
Statistical Model 
 
A Cox proportional hazards model was developed that utilized interactions 
between vaccination and year. Influenza vaccination was coded as a time-
varying variable. The model was specified as: 
 ( )      (  (          )    (      )    (      )    (      )    (           
      )    (                 )    (                 )    
  )  
 
where    
  was the transpose of the vector of log hazard ratios for each of the 
remaining covariates L. For some analyses, patients could be included in multiple 
cohorts and thus have multiple outcomes, thus a robust variance estimator was 
inspected that would account for the non-independence of the data. The variance 
did not change when using the robust variance; thus, the standard estimates 
were reported. 
Additional Analyses 
Several sensitivity analyses were conducted for Aim 1. First, the model 
was stratified by center. This was done because it was hypothesized that 
individual dialysis centers may have similar protocols for influenza vaccination, 
including the amount of encouragement given to patients to get vaccinated. 
Second, we ended follow-up at the approximate end of flu season. The survival 
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curves crossed at approximately the end of each flu season; therefore, the 
analysis was limited to the time prior to the crossing hazards. Because of the way 
the model was specified (i.e., includes all years in one model), we chose the year 
with the latest end of influenza season to be the end of follow-up for this 
sensitivity analysis. 
In addition, the model was estimated stratified by age, vintage, and cause 
of ESRD. We hypothesized that the level of immune function and thus the 
vaccine effectiveness could vary within levels of these variables. We thought that 
immune function, and perhaps vaccine effectiveness would decrease with 
increasing age and with increasing time on dialysis. The cause of ESRD might 
also affect how well a person responds to the vaccine.  
 Methods pertaining to Specific Aim Two F.
Exposure Measure 
The exposure measures were time-varying hospitalization and skilled 
nursing care status as defined in Section B. Only hospitalizations or skilled 
nursing care initiated prior to or on the same day as vaccination were counted. 
Patients could have multiple hospitalizations or admissions to skilled nursing 
facilities. Pooled logistic model coding was used to create the time-varying 
exposure.  
Statistical Model 
 
Two separate models were developed to assess hospitalization and 
skilled nursing care. Separate Cox proportional hazards models with time-varying 
exposure coding were developed to estimate hazard ratios of vaccination for 
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each exposure. Because the data was structured into a person-week format, the 
exposure variables were updated each week. Follow-up began on September 1 
of each year and continued until the patient was vaccinated, died, was lost to 
follow-up or was administratively censored on December 31 of each year. For 
both exposures, we fit models that categorized hospitalization and skilled nursing 
days into temporary (1 day), short (2–3 days), medium (4–14 days), medium-long 
(15–25 days), and long stays (26–30 days), with zero days as the referent. This 
model was specified as:  
 ( )  
   (  (     )    (       )     (        )    (         )  
  (         )    
  )   
 
where    
  was the transpose of the vector of log HRs for each of the remaining 
covariates L. The model for skilled nursing care was specified in the same 
manner. 
 Methods pertaining to Specific Aim Three G.
 
Cox proportional hazards marginal structural model 
This marginal structural model models potential outcomes of death as if 
vaccination were randomized within the population.19 For this analysis, the origin 
was September 1 for each year and patients were followed until August 31 of the 
subsequent year.  The analysis was also limited to the pre-influenza period to 
assess bias.  The marginal structural model was estimated using inverse 
probability of treatment weights (IPTW). The IPTW create a “pseudo-population” 
where each subject is weighted by the inverse of the conditional probability of 
receiving the exposure that they actually did receive.20 Thus, subjects with 
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infrequent covariate combinations are up-weighted and subjects with covariate 
patterns that are frequently represented in treatment assignment are down-
weighted. Both time-fixed and time-varying confounders should be distributed 
equally across vaccination groups in the pseudo-population. Vaccine 
effectiveness is then estimated by comparing vaccinated to unvaccinated 
patients within this unconfounded pseudo-population.  
The Cox proportional hazard marginal structural model is specified as: 
   ̅( )    ( )      (        
    ) 
where    ̅( ) is the potential hazard of death at time t under treatment history  ̅,  
  ( ) is the unspecified baseline hazard of death in the unvaccinated,     is a 
time-varying indicator variable for vaccination status prior to day t  for subject i, 
   is the log HR comparing vaccinated with unvaccinated,     is a vector of 
measured baseline covariates, and   
  is the transpose of the vector of log HRs 
for each of the baseline covariates. The model specified earlier will be estimated 
using IPTW and is specified as: 
 
  ̅
    ( )    ( )      (        
    ) 
where the hazard of death is weighted by the observed treatment  ̅. Here   =    
under the assumptions of consistency, positivity, correctly specifying the weight 
models, and no unmeasured confounding.21 
To estimate the IPTW we fit a logistic model that treats each person-week 
as an observation (i.e., time-varying weights were estimated for each week of 
follow-up, from September 1 through August 31 of the following year). The 
weights were calculated from the predicted values outputted from the logistic 
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procedure using prior time–varying confounders, baseline confounders, and prior 
time-varying treatment as predictor variables. Patients were considered to be 
censored upon loss to follow-up or end of study (August 31 of following year).  
The stabilized inverse probability of treatment weight is given as: 
    
  ∏
      | ̅           ̅      
      | ̅      ̅       ̅      
 
   
 
Here the numerator is the probability of person i being vaccinated given their past 
exposure history ( ̅    ), their baseline covariates (   ), and that they weren’t 
censored in the preceding week (  ̅     ). This weight is stabilized because we 
are including the baseline covariates in the numerator. The denominator is the 
probability of person i being vaccinated given their past exposure history ( ̅    ), 
their time–varying covariates (which include their baseline covariates) ( ̅    ), 
and that they weren’t censored in the preceding week (  ̅     ).  
Exploring model assumptions 
For marginal structural models to correctly estimate the causal effect of 
the exposure on the outcome, several assumptions must be made including: 
consistency, positivity, correctly specifying the weight models, and no 
unmeasured confounding. These assumptions were explored to determine if they 
were met in this analysis. First, the positivity assumption was checked for 
important confounders. For all levels of confounders there should be some 
subjects who are exposed. For example, there should be patients who were 
vaccinated with a range of hospital days in the past 30 days. Because very few 
patients were vaccinated in the hospital, recent hospitalization and skilled nursing 
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care were modeled both as functions of a linear term, as well as in quintiles to 
ameliorate any positivity issues. Next, the assumption of no unmeasured 
confounding was explored by specifying different functional forms for continuous 
variables and including a variety of confounders deemed important by subject-
matter experts. Finally, the assumption of correctly specifying the weight model 
was explored by examining the distribution of the weights (i.e., mean, standard 
deviation, minimum and maximum). The stabilized weights should have a mean 
of one. Weights with extreme values or means that are not close to one, could 
indicate a miss-specification of the weight model or non-positivity.21 Patients who 
received extreme weights (usually weights greater than 20 are considered 
extreme) are up-weighted heavily in the pseudo-population. These are often 
people who represent the extremes of the population and should not always be 
so influential to the final average estimate in the population. Therefore, weights 
with extreme values can be trimmed. However, in our analysis, we did not find 
extreme weights, therefore trimming was not necessary.  
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V. RESULTS: “EVALUATING INFLUENZA VACCINE EFFECTIVENESS 
AMONG PATIENTS ON HEMODIALYSIS USING A NATURAL 
EXPERIMENT” 
 
 Introduction A.
Influenza causes substantial morbidity and mortality in the general 
population with approximately 39,000 people dying each year.1 Patients with 
ESRD may be at higher risk of illness and death from influenza relative to healthy 
adults. For more than 40 years, trivalent inactivated influenza vaccine has been 
recommended by the Advisory Committee on Immunization Practices for patients 
with ESRD.2 Seasonal influenza vaccination has become routine practice at most 
dialysis clinics during the past two decades. Although patients on hemodialysis 
have lower response rates to influenza vaccine compared with healthy adults, 
immunogenicity studies show that 50-93% of patients undergoing dialysis 
develop antibody titers after vaccination.3,4 However, it is currently unclear how 
much morbidity and mortality is prevented by the influenza vaccine in patients 
with ESRD.5 To date, one study among patients on hemodialysis has estimated 
a12% to 14% VE for influenza/pneumonia hospitalizations and 25% for all-cause 
mortality.6 Recent studies in the elderly population who are not on dialysis have 
suggested that large VE effects (up to 50% reduction of all-cause mortality in 
some studies 7-9) obtained from standard epidemiologic studies may be the result 
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of to confounding by unmeasured prognostic variables, and the true effect may 
be small to negligible.10-14  
 One potential way to avoid confounding by patient-level differences is to 
exploit the natural experiment that is caused by strong year-to-year variation in 
the match of the vaccine to the circulating strain. The influenza virus that 
predominates in a season can undergo antigenic drift after the vaccine strain has 
been chosen, resulting in a vaccine that provides reduced immunity. In seasons 
with a well-matched vaccine, vaccination is expected to be effective in preventing 
influenza related outcomes, whereas in mismatched seasons, vaccination is 
expected to have a minimal effect. It has been documented that the 1997–98 
influenza vaccine strain (A/Wuhan/359/95) did not match the circulating strain 
(A/Sydney/5/97) 15 and outbreak investigations suggested that the vaccine 
provided limited protection.16 A randomized controlled trial confirmed that the 
vaccine did not prevent clinically relevant outcomes during this season among 
healthy adults younger than 65 years:  vaccinated patients had more influenza-
like illnesses (ILI) and upper respiratory tract infections than patients receiving 
placebo.17 In three of the following four years, the same strain of virus circulated 
in the community, and the vaccine was well matched.18-20  
We evaluated the difference in VE between years in which the vaccine 
was well matched and the 1997–98 “placebo” year, in which the vaccine was 
poorly matched and was shown to have provided little benefit.  By studying this 
natural experiment, we sought to reduce confounding bias due to frailty and 
unmeasured health behaviors to obtain a more accurate measure of VE. 
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 Methods B.
 
Study Population 
We used Medicare claims from the United States Renal Data System, a 
population-based national system that collects information on all patients with 
ESRD in the United States. Claims include information on physician services, 
codes from the International Classification of Diseases, 9th revision, Clinical 
Modification (ICD-9-CM) assigned to hospitalizations and outpatient care; and 
information on dialysis care, medication, and immunization use. This information 
is captured for all patients with Medicare as a primary payer (no health 
maintenance organization insurance as a primary payer, or Medicare as a 
secondary payer).   
Our cohorts consisted of all adult, patients with ESRD who had Medicare 
as a primary payer and underwent continuous hemodialysis use. Each yearly 
cohort consisted of patients who had initiated dialysis before October 1 of the 
preceding year. An eight month window from January 1 – August 31 of each year 
was used to identify insurance and comorbidities for the patients in that cohort. A 
three-month window from June 1 through August 31 was used to identify 
continuous hemodialysis status. For example, the cohort identified for the 1997-
98 season would have initiated dialysis before October 1, 1996 and would have 
been receiving continuous hemodialysis from June 1 through August 31, 1997 
and had Medicare as a primary payer from January 1 – August 31, 1997. 
Vaccination and outcome status were assessed beginning on September 1 of 
each year. Cohort members were followed each year until they experienced one 
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of the three study outcomes, death (for non-mortality outcomes), transplant, loss 
to follow–up, or administrative censoring on August 31 of the following year (e.g. 
August 31, 1998 for the 1997 influenza season).  
Influenza Seasons 
We chose to analyze specific years based on the characteristics of each 
influenza season: years with similar influenza severity and in temporal proximity 
to the mismatched season. We used years before paying out of pocket at grocery 
stores or pharmacies became common to limit exposure misclassification. 
Cohorts were created for the following influenza seasons: 1997, 1998, 1999, and 
2001. Seasons were defined by the year in which vaccination began for that 
influenza season (e.g., the 1997–1998 season was defined as 1997). These four 
seasons were used because of their similar severity and strain of influenza, but 
various levels of vaccine match (i.e., how well the vaccine matched the strain 
circulating in the community).15,18-20 We excluded the 2000 season to limit 
differences between seasons due to influenza severity; the predominate strain in 
the community in 2000 was a less severe strain (A/H1N1).21 We estimated the 
start of each influenza season by using national influenza surveillance data from 
the CDC. We defined the start of the season as the midpoint of the first week 
during which more than 10% of the isolates were positive for influenza. A 
sensitivity analysis examined the effect of a less restrictive definition, with the 
start of the season defined as the week with 5% of isolates positive for influenza. 
Vaccination Status 
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Medicare Part A hospital/outpatient files and Part B physician/supplier files 
were searched for Current Procedural Terminology codes 90724, 90656, and 
90658-60, and Health Care Financing Administration Common Procedure Coding 
System codes G0008 and G8482. Because our study population is often 
hospitalized, we also searched for ICD-9-CM procedure code 99.52. 
Outcomes 
We examined the following three outcomes: all-cause mortality, 
influenza/pneumonia hospitalization and ILI. Mortality was identified by the 
Centers for Medicare and Medicaid Services form 2746, the ESRD Death 
Notification Form. We searched the principal discharge diagnoses in the 
Medicare Part A inpatient hospitalization files for the first instance of ICD-9-CM 
codes 480.xx – 487.xx to identify influenza/pneumonia hospitalizations. Inpatient 
and outpatient codes were searched to identify the first instance of ILI as 
classified by Lindsay, et al22 (Table 7). In a sensitivity analysis, we limited ILI to 
more specific codes by removing ICD-9-CM codes 465, 466, and 490.  
Covariates 
All confounders were identified using the existing evidence base – 
including the investigative team’s knowledge and the published literature. We 
used the Centers for Medicare and Medicaid Services form 2827, the Medical 
Evidence Form, to ascertain age, race, sex, first service date with ESRD, and 
cause of kidney failure. Parts A and B claims were searched during the eight–
month window from January 1 to August 31 for oxygen use and the following 
comorbidities as identified by Liu et al.23: atherosclerotic heart disease, 
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congestive heart failure, cerebrovascular accident/transient ischemic attack, 
peripheral vascular disease, other cardiac disease, chronic obstructive 
pulmonary disease, gastrointestinal tract bleeding, liver disease, dysrhythmia, 
cancer, and diabetes mellitus (Appendix 1). Comorbidities were modeled as 
dichotomous variables in the final models. Adherence to dialysis was calculated 
by summing the number of dialysis sessions during the eight–month baseline 
period:  patients were considered adherent if they had 95 sessions or more.  
Patients with no dialysis sessions during the baseline period were dropped from 
the analysis. We also included the number of hospital days during the baseline 
period. Use of mobility aids was ascertained by searching Parts A and B claims 
for Health Care Financing Administration Common Procedure Coding System 
equipment codes for wheelchairs, walkers, canes, and bathroom assistance 
equipment during the baseline period (Table 9).  
Statistical Analysis 
We used Cox proportional hazards models to estimate hazard ratios 
(HRs) comparing vaccinated with unvaccinated cohorts within each year.24 
Vaccination was modeled as a time-varying covariate, with all cohort members 
entering the analysis on September 1 as unvaccinated. Once vaccinated, 
patients remained in the vaccinated category until the end of that influenza year 
(August 31). To quantify bias in these estimates, we ran the same models during 
the pre-influenza period (September 1 through the day before the influenza 
season started). When limited to the period before the start of influenza season 
when vaccine effectiveness should be biologically negligible, we would expect 
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the HR estimate to be close to 1.0 if no confounding was present. This method 
identifies whether the conventional analysis remains biased even after 
adjustment. 
To estimate effects between seasons, we ran proportional hazards models 
with an interaction between vaccination status and year, with vaccination status 
treated as described in the preceding paragraph. Kaplan-Meier survival curves 
are reported for the comparison of different years among vaccinated patients. We 
report the antilog of the beta coefficient for the interaction term, which represents 
the ratio of two HRs: comparing the vaccinated cohort in a matched year with the 
vaccinated cohort in the unmatched year divided by the comparison of the 
unvaccinated cohort in a matched year with the unvaccinated cohort in the 
unmatched year. We calculated VE as 1 – effect measure. Because patients 
could be in multiple cohorts, robust variance was used initially to account for the 
possibility of having multiple events in the analysis of events other than mortality. 
Using robust variance did not change the variance estimate; thus, we report 
standard variances. 
Adjusted models in all analyses controlled for age, race, sex, cause of 
ESRD, length of time with ESRD (vintage), adherence to dialysis, number of 
mobility aids as a proxy for functional status, oxygen use, hospital days, ESRD 
network and comorbidities. The proportional hazard assumption was checked 
graphically. To examine the effect of non-proportional hazards, we limited our 
final model to run only through the end of the influenza season, which is 
approximately the time when the curves crossed. The analysis was conducted 
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using SAS 9.2 (Cary, NC) using Efron’s method for tied event times.25 This study 
was considered exempt from human subjects review by the institutional review 
board at the University of North Carolina.  
 Results C.
 
More than 100,000 patients met the inclusion criteria in each influenza 
season cohort, and vaccination rates were approximately 48% each year, similar 
to previously reported estimates (Table 11).6,26 Patients who received the 
influenza vaccine were older, had fewer years with ESRD, were more likely to be 
White, and had better adherence to dialysis. These differences persisted during 
the study period. In addition, the mean age of the vaccinated cohorts increased, 
and the proportion who had diabetes mellitus as the cause of ESRD increased 
during the study period.  
The A/H3N2 strain predominated in all the influenza seasons, and all were 
severe influenza seasons. The start of the influenza seasons ranged from late 
November to early January (Table 12).  
Conventional analysis comparing vaccinated with unvaccinated patients 
resulted in average, adjusted VE estimates of 13%, 16%, and 30% for ILI, 
influenza/pneumonia hospitalization, and death, respectively (Table 13). 
Adjustment for measured confounders increased all VE estimates slightly. 
However, when limited to the period before the start of influenza season the 
estimates were similar or stronger, which strongly suggests that confounding bias 
was present. The adjusted HR for death in the pre-influenza period ranged from 
0.36 to 0.51, indicating that there was severe bias in the comparison between 
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vaccinated and unvaccinated cohorts for the outcome of all-cause mortality. 
Defining the start of influenza season with an earlier date (with 5% of isolates 
positive) resulted in even more biased estimates (Table 13).  
Vaccinated patients in all matched years had more events than did 
vaccinated patients in the unmatched year, and there was little difference in the 
survival curves for each outcome (Figure 3). The models for 1998 versus 1997 
and 1999 versus 1997 produced similar results, showing no benefit for any of the 
three outcomes. The comparison between 2001 and 1997 produced a small 
beneficial effect. The pooled ratio of HRs comparing matched seasons with a 
placebo season resulted in a VE of 0% (95% CI: -3,2%) for ILI, 2% (-2,5%) for 
influenza/pneumonia hospitalization, and 0% (-3,3%) for death (Table 14). 
Neither limiting the model to run only through the end of the influenza season 
(data not shown) nor restricting the ILI definition (Table 15) appreciably changed 
the estimates. Starting follow-up on December 1 resulted in slightly stronger 
estimates, with the confidence intervals for ILI and hospitalization excluding the 
null (Table 15).  
 Discussion D.
 
 In this population-based study, we analyzed the natural experiment 
created by year-to-year variation in the match of the influenza vaccine to the 
circulating virus. We used the vaccine during a mismatched year as a working 
“placebo” and compared its effectiveness to well-matched vaccines in 
subsequent years. We found little evidence that the well-matched vaccines were 
more effective than the mismatched vaccine for the prevention of ILI, 
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influenza/pneumonia hospitalization and all-cause mortality among patients on 
hemodialysis.  
We also conducted traditional analyses comparing vaccinated and 
unvaccinated patients. These analyses revealed strong evidence of unobserved 
confounding. In all years, we found that the vaccinated patients were at 
decreased risk for all outcomes even before influenza began circulating in the 
community. Despite adjusting for many clinical factors, these analyses remained 
biased. Comparing patients who are vaccinated in one year with patients who are 
vaccinated in another year implicitly controlled for unmeasured aspects of health, 
functional status, and health behaviors that may differ between the vaccinated 
and unvaccinated cohorts.27  
 Patients with ESRD have some level of immune dysfunction that may limit 
their ability to respond adequately to the influenza vaccine. Specifically, these 
patients have fewer B-cells because of apoptosis and inflammatory cytokines 
pushing immune cell differentiation toward the T-cell pathway.28,29 Although 
immunogenicity studies have shown that patients with ESRD can produce 
antibodies, antibody production may not be sufficient to provide protection from 
influenza infection.  
Because patients with ESRD may have levels of immune deficiency 
similar to those of elderly individuals, our results are consistent with recent work 
in the elderly population. Fireman et al. reported an estimate of VE for all-cause 
mortality of 5% (1,8%),30 whereas Baxter et al. reported estimates for 
influenza/pneumonia hospitalizations of 12% (2,22%) in persons aged 50–64, 
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and 9% (3,14%) in those 65 years or older.14 Jackson et al. estimated VE for 
community-acquired pneumonia among elderly individuals as 8% (-10,23%).12 
Caution is needed, however, in comparing patients who have ESRD with the 
general elderly population. Patients with ESRD are seen at medical facilities 2-3 
times per week for dialysis, therefore the reasons for being vaccinated may be 
different.  
 Our results comparing various influenza seasons differed from a previous 
observational study of influenza VE in ERSD patients. The previous study 
compared vaccinated with unvaccinated patients and reported VE estimates 
during the 1998–99 matched season of 14% (8%, 23%) for influenza/pneumonia 
hospitalizations and 23% (19%, 27%) for all-cause mortality.6 These results were 
similar to our conventional adjusted estimates. By limiting our conventional 
analysis to the pre-influenza period, we showed that the traditional epidemiologic 
approach may exaggerate the benefits of vaccination.   
 There are limitations to this study. First, we assumed that the vaccine was 
ineffective in preventing clinical outcomes in the 1997 season. If the vaccine 
provided some benefit, the difference in effectiveness between the match and the 
mismatched years would be narrowed, and thus our estimate would be closer to 
the null than the true estimate. However, evidence from a randomized controlled 
trial showed that the vaccine did not protect against clinical outcomes among 
younger, healthier people.17 Moreover, the vaccine is even less likely to have 
provided protection to an immune-compromised population. Second, because we 
used administrative claims data, we may have not adequately captured all the 
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important confounders, particularly variables that changed between years, such 
as quality of care, temperature variations, or other circulating viruses. We did, 
however, adjust for a variety of clinical characteristics, and this is the first study to 
our knowledge to account for adherence to dialysis, which may be an important 
predictor of exposure to preventive healthcare services. In addition, we limited 
the comparisons to a five year period to limit temporal changes. Third, it is likely 
that the ILI outcome was under-ascertained. Unless physicians were making their 
diagnosis in part on the basis of the patient’s vaccination status during the visit, 
this misclassification would be non-differential. If a true effect did exist, we would 
expect the estimate to be stronger for a more specific influenza outcome, such as 
ILI, compared with a less specific outcome, such as mortality. Our estimates did 
not reflect this trend; therefore, it is possible that our estimate for ILI may be 
biased toward the null. Finally, we may have missed some vaccinations if 
patients received a vaccine that was paid out of pocket. Because influenza 
vaccine is covered by Medicare for our study population and because patients 
undergoing dialysis have healthcare encounters 2 to 3 times per week, we 
expect that the number of people who paid out of pocket would be low. These 
limitations cannot rule out a protective effect of the vaccine; however, we think 
our findings suggest that the effect may be smaller than previously believed.  
The findings of this study should not be interpreted to mean that the 
practice of influenza vaccination be discouraged. Rather, they suggest that 
current strategies for vaccination, which rely on single dosing with a trivalent 
inactivated influenza virus, should be re-evaluated. Alternative vaccine 
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formulations exist and may be more suitable for the dialysis population. For 
example, adjuvants such as AS03 and MF59 can act as a delivery system for the 
virus and potentiate the immunogenic response. One recent study demonstrated 
a significantly higher antibody response in patients on hemodialysis who use the 
AS03a adjuvant vaccine compared with the standard vaccine.31 A high-dose 
vaccine that contains three times the amount of virus compared with standard 
vaccine, also offers an alternative strategy. Future studies should examine the 
clinical effectiveness of these alternate vaccination strategies. 
In summary, our analysis suggests that the potential health benefits of the 
current influenza vaccine may be small to negligible in the dialysis population. 
Conventional analyses comparing vaccinated with unvaccinated groups are 
prone to bias. Although it is premature to discontinue vaccinating high-risk 
patients, alternate vaccination strategies should be investigated in patients with 
ESRD to achieve better health outcomes.  
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 Tables and Figures E.
 
Table 11. Description of study cohorts 
 
     
Variable 1997 1998 1999 2001 
 Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated Vaccinated Unvaccinated 
 N=52,287 N=55,178 N=53,884 N=59,225 N=56,796 N=60,248 N=61,800 N=64,899 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
         
Mean age (SD) 62.3 (14.2) 60.3 (15.0) 62.7 (14.1) 60.6 (15.0) 63.1 (14.2) 61.0 (14.9) 63.9 (14.0) 61.7 (14.8) 
Male sex 27,310  (52.2) 27,827 (50.4) 28,363 (52.6) 30,213 (51.0) 29,963 (52.8) 30,621 (50.8) 32,727 (53.0) 33,476 (51.6) 
Race         
   White 29,625 (56.7) 25,975 (47.1) 30,744 (57.1) 27,857 (47.0) 32,100 (56.5) 28,606 (47.5) 35,571 (57.6) 31,631 (48.7) 
   Black 20,443 (39.1) 26,384 (47.8) 20,659 (38.3) 28,271 (47.7) 21,978 (38.7) 28,428 (47.2) 23,150 (37.5) 29,629 (45.7) 
   Other 2,219 (4.2) 2,819 (5.1) 2,481 (4.6) 3,097 (5.2) 2,718 (4.8) 3,214 (5.3) 3,079 (5.0) 3,639 (5.6) 
Cause of ESRD         
   Diabetes 19,988 (38.2) 20,277 (36.7) 21,453 (39.8) 22,550 (38.1) 23,336 (41.1) 23,614 (39.2) 26,457 (42.8) 27,044 (41.7) 
   Hypertension 16,503 (31.6) 18,055 (32.7) 16,650 (30.9) 18,947 (32.0) 17,207 (30.3) 18,988 (31.5) 18,365 (29.7) 19,923 (30.7) 
   Glomerulonephritis 6,998 (13.4) 7,595 (13.8) 6,931 (12.9) 8,002 (13.5) 7,114 (12.5) 7,842 (13.0) 7,300 (11.8) 7,784 (12.0) 
   Cystic Kidney 1,838 (3.5) 1,677 (3.0) 1,781 (3.3) 1,705 (2.9) 1,772 (3.1) 1,649 (2.7) 1,739 (2.8) 1,643 (2.5) 
   Other 6,960 (13.3) 7,574 (13.7) 7,069 (13.1) 8,021 (13.5) 7,367 (13.0) 8,155 (13.5) 7,939 (12.8) 8,505 (13.1) 
1 or more mobility aid  4,096 (7.8) 4,767 (8.6) 3,840 (7.1) 4,563 (7.7) 3,910 (6.9) 4,141 (6.9) 4,080 (6.6) 4,411 (6.8) 
Vintage (years)         
   0  1,048 (2.0) 1,092 (2.0) 1,212 (2.2) 1,267 (2.1) 1,211 (2.1) 1,208 (2.0) 1,211 (2.0) 1,247 (1.9) 
   1-2  22,345 (42.7) 22, 313 (40.4) 22,715 (42.2) 23,473 (39.6) 23,750 (41.8) 23,667 (39.3) 25,283 (40.8) 25,279 (39.0) 
   3-4  13,588 (26.0) 13,867 (25.1) 13,944 (25.9) 14,976 (25.3) 14,644 (25.8) 14,868 (24.4) 16,214 (26.2) 16,244 (25.0) 
   5-9  11,154 (21.3) 12,521 (22.7) 11,783 (21.9) 13,766 (23.2) 12,981 (22.9) 14,247 (23.6) 14,042 (22.7) 15,725 (24.2) 
   10+ 4,152 (7.9) 5,385 (9.8) 4,230 (7.9) 5,743 (9.7) 4,210 (7.4) 6,258 (10.4) 5,050 (8.2) 6,404 (9.9) 
Adherent to dialysis 45,103 (86.3) 43,760 (79.3) 48,130 (89.3) 48,103 (81.2) 50,383 (88.7) 49,028 (81.4) 55,611 (90.0) 53,753 (82.8) 
Mean hospital days (SD) 8.4 (14.8) 10.3 (18.1) 8.3 (14.6) 10.5 (18.3) 8.6 (15.2) 11.0 (19.0) 8.9 (15.8) 11.6 (19.6) 
Oxygen Use 5,090 (9.7) 6,085 (11.0) 5,574 (10.3) 6,890 (11.6) 6,218 (10.9) 7,954 (13.2) 7,258 (11.7) 9,058 (14.0) 
Atherosclerotic heart dis. 17,993 (34.4) 18,675 (33.8) 17,886 (33.2) 19,050 (32.2) 19,478 (34.3) 19,901 (33.0) 23,584 (38.2) 24,461 (37.7) 
Congestive heart failure 18,572 (35.5) 20,585 (37.3) 17,885 (33.2) 20,961 (35.4) 19,174 (33.8) 21,444 (35.6) 22,408 (36.3) 25.428 (39.2) 
TIA 7,197 (13.8) 8,602 (15.6) 6,725 (12.5) 8,540 (14.4) 7,102 (12.5) 8,389 (13.9) 8,675 (14.0) 10,430 (16.1) 
Peripheral vascular dis. 16,028 (30.7) 17,680 (32.0) 15,315 (28.4) 17,794 (30.0) 16,423 (28.9) 17,938 (29.8) 19,759 (32.0) 21,761 (33.5) 
Other cardiac disease 13,950 (26.7) 15,004 (27.2) 12,602 (23.4) 14,684 (24.8) 13,693 (24.1) 14,933 (24.8) 16,178 (26.2) 18,084 (27.9) 
Liver disease 13,060 (25.0) 14,513 (26.3) 3,712 (6.9) 4,853 (8.2) 3,005 (5.3) 4,267 (7.1) 2,705 (4.4) 3,556 (5.5) 
COPD 7,563 (14.5) 8,406 (15.2) 7,435 (13.8) 8,523 (14.4) 8,207 (14.4) 8,932 (14.8) 10,104 (16.3) 11,210 (17.3) 
Gastrointestinal bleed 5,212 (10.0) 6,191 (11.2) 5,118 (9.5) 6,215 (10.5) 5,108 (9.0) 6,182 (10.3) 5,706 (9.2) 6,951 (10.7) 
Dysrhythmia 13,354 (25.5) 13,883 (25.2) 11,443 (21.2) 12,745 (21.5) 12,129 (21.4) 13,123 (21.8) 14,158 (22.9) 15,547 (24.0) 
Cancer 4,031 (7.7) 4,161 (7.5) 3,272 (6.1) 3,648 (6.2) 3,331 (5.9) 3,501 (5.8) 3,897 (6.3) 4,028 (6.2) 
Diabetes 26,598 (50.9) 27,609 (50.0) 26,106 (48.4) 28,402 (48.0) 27,819 (49.0) 28,690 (47.6) 32,682 (52.9) 33,863 (52.2) 
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Table 12. Description of influenza seasons 
 1997 1998 1999 2001 
% Serologic Match 19% 90% 97% 100% 
Predominate strain A(H3N2) A(H3N2), B A(H3N2) A(H3N2), B 
Start of flu season (10%) 12/31/1997 1/13/1999 11/24/1999 1/9/2002 
Start of flu season (5%) 12/24/1997 12/30/1998 11/10/1999 12/19/2001 
 
 
 
Table 13. Estimates of vaccine effectiveness comparing vaccinated vs. unvaccinated by year  
Year No. 
Events 
No. Lost/ 
Transplant 
Crude HR 
95% CI 
Adjusted HR
* 
95% CI 
Adjusted HR in 
pre-flu period
† 
95% CI 
Adjusted HR in 
pre-flu period
‡ 
95% CI 
1997       
   ILI 30,107 2,807 0.95 (0.93, 0.97) 0.89 (0.87, 0.91) 0.90 (0.88, 0.92) 0.76 (0.73, 0.79) 
   Influenza/Pneumonia hosp. 16,081 3,035 0.92 (0.89, 0.95) 0.86 (0.83, 0.89) 0.87 (0.85, 0.90) 0.75 (0.70, 0.80) 
   Death 23,397 3,144 0.77 (0.75, 0.79) 0.70 (0.68, 0.72) 0.48 (0.46, 0.51) 0.47 (0.44, 0.49) 
1998       
   ILI 33,552 2,848 0.94 (0.92, 0.96) 0.88 (0.86, 0.90) 0.77 (0.74, 0.80) 0.74 (0.71, 0.77) 
   Influenza/Pneumonia hosp. 17,969 3,048 0.91 (0.88, 0.94) 0.84 (0.81, 0.87) 0.75 (0.71, 0.80) 0.73 (0.68, 0.78) 
   Death 25,768 3,159 0.79 (0.77, 0.81) 0.72 (0.70, 0.74) 0.51 (0.48, 0.53) 0.46 (0.44, 0.49) 
1999       
   ILI 34,837 2,783 0.94 (0.92, 0.96) 0.87 (0.85, 0.89) 0.67 (0.64, 0.71) 0.62 (0.58, 0.66) 
   Influenza/Pneumonia hosp. 18,893 3,020 0.90 (0.87, 0.93) 0.84 (0.81, 0.86) 0.63 (0.58, 0.68) 0.56 (0.51, 0.62) 
   Death 26,904 3,150 0.76 (0.74, 0.78) 0.70 (0.68, 0.72) 0.36 (0.33, 0.39) 0.28 (0.25, 0.31) 
2001       
   ILI 40,768 3,031 0.90 (0.88, 0.92) 0.86 (0.84, 0.88) 0.76 (0.73, 0.79) 0.69 (0.66, 0.72) 
   Influenza/Pneumonia hosp. 22,658 3,280 0.87 (0.85, 0.90) 0.82 (0.80, 0.85) 0.71 (0.68, 0.76) 0.64 (0.60, 0.69) 
   Death 30,221 3,417 0.76 (0.74, 0.78) 0.70 (0.68, 0.71) 0.46 (0.44, 0.49) 0.40 (0.37, 0.43) 
* 
Adjusted for age, race, sex, cause of ESRD, vintage, adherence, hospital days, mobility aids, network, comorbidities, and oxygen use 
† 
Pre-flu period as defined by 10% of isolates positive for influenza 
‡ 
Pre-flu period as defined by 5% of isolates positive for influenza 
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Table 14. Ratio of hazard ratios (RHR) that estimate VE by comparing matched versus mismatched years among 
vaccinated versus unvaccinated  
 1998 vs. 1997  1999 vs. 1997  2001 vs. 1997  Pooled vs. 1997 
 Crude RHR 
95% CI 
Adjusted RHR
* 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
        
ILI 1.03 (1.00, 1.07) 1.03 (1.00, 1.07) 1.01 (0.98, 1.04) 1.00 (0.97, 1.03) 0.97 (0.94, 1.00) 0.98 (0.95, 1.01) 1.00 (0.98, 1.03) 
I/P hosp. 1.02 (0.97, 1.06) 1.01 (0.97, 1.06) 1.00 (0.96, 1.05) 0.99 (0.95, 1.04) 0.95 (0.92, 0.99) 0.95 (0.91, 0.99) 0.98 (0.95, 1.02) 
Death 1.03 (0.99, 1.06) 1.02 (0.99, 1.06) 0.99 (0.96, 1.03) 1.00 (0.96, 1.03) 0.99 (0.96, 1.03) 0.99 (0.96, 1.03) 1.00 (0.97, 1.03) 
* 
Adjusted for age, race, sex, cause of ESRD, vintage, adherence, hospital days, mobility aids, network, comorbidities, and oxygen use 
** 
Influenza/pneumonia 
 
 
 
Table 15. Sensitivity analyses of ratio of hazard ratios (RHR) that estimate VE  
 1998 vs. 1997  1999 vs. 1997  2001 vs. 1997  Pooled vs. 1997 
 Crude RHR 
95% CI 
Adjusted RHR
* 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
        
Specific ILI 
codes 
1.04 (1.00, 1.07) 1.03 (1.00, 1.06) 1.01 (0.98, 1.04) 1.00 (0.97, 1.03) 0.97 (0.94, 1.00) 0.98 (0.95, 1.02) 1.00 (0.98, 1.03) 
        
Start follow-up  
on 12/1 
       
   ILI 1.00 (0.97, 1.04) 0.99 (0.96, 1.03) 0.98 (0.95, 1.02) 0.97 (0.93, 1.00) 0.93 (0.90, 0.96) 0.94 (0.91, 0.97) 0.97 (0.94, 0.99) 
   I/P Hosp. 0.98 (0.94, 1.03) 0.98 (0.93, 1.02) 0.99 (0.94, 1.03) 0.97 (0.93, 1.02) 0.92 (0.88, 0.96) 0.93 (0.89, 0.97) 0.96 (0.92, 0.99) 
   Death 1.01 (0.97, 1.05) 1.01 (0.97, 1.06) 0.99 (0.95, 1.03) 1.00 (0.96, 1.04) 0.95 (0.91, 0.99) 0.95 (0.92, 0.99) 0.99 (0.95, 1.02) 
* 
Adjusted for age, race, sex, cause of ESRD, vintage, adherence, hospital days, mobility aids, network, comorbidities, and oxygen use 
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Figure 3. Unadjusted, pooled survival curves among the vaccinated for A) ILI B) Influenza/pneumonia 
hospitalization C) Death 
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 Additional Subgroup Results F.
 
Table 16. Ratio of HRs by age.  
 
 
 
 
 
 
  1998 vs. 1997   1999 vs. 1997   2001 vs. 1997   Pooled vs. 1997 
  Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Crude RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
65+ years               
ILI 1.09 (1.04, 1.14) 1.08 (1.03, 1.13) 1.02 (0.98, 1.06) 1.01 (0.96, 1.05) 0.98 (0.94, 1.02) 1.00 (0.96, 1.04) 1.03 (0.99, 1.06) 
Flu/pneumo hosp 1.06 (1.00, 1.12) 1.05 (0.99, 1.11) 1.03 (0.97, 1.08) 1.02 (0.97, 1.07) 0.95 (0.91, 1.00) 0.97 (0.92, 1.02) 1.01 (0.96, 1.05) 
Death 1.05 (1.00, 1.10) 1.04 (1.00, 1.09) 1.01 (0.97, 1.06) 1.01 (0.97, 1.06) 1.00 (0.95, 1.04) 1.01 (0.96, 1.05) 1.02 (0.98, 1.06) 
                
<65 years               
ILI 0.98 (0.93, 1.02) 0.97 (0.93, 1.02) 1.00 (0.96, 1.05) 0.99 (0.95, 1.04) 0.96 (0.92, 1.00) 0.97 (0.92, 1.01) 0.98 (0.94, 1.02) 
Flu/pneumo hosp 0.97 (0.91, 1.03) 0.96 (0.90, 1.02) 1.00 (0.94, 1.06) 0.98 (0.93, 1.05) 0.94 (0.89, 1.00) 0.94 (0.89, 1.00) 0.96 (0.91, 1.01) 
Death 0.98 (0.92, 1.04) 0.98 (0.92, 1.04) 0.94 (0.89, 1.00) 0.94 (0.89, 1.00) 0.98 (0.92, 1.04) 0.97 (0.91, 1.03) 0.96 (0.92, 1.01) 
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Table 17. Ratio of HRs by cause of ESRD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1998 vs. 1997 1999 vs. 1997 2001 vs. 1997 Pooled vs 1997 
  Adjusted RHR* 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
Diabetes         
ILI 1.05 (1.00, 1.11) 1.01 (0.96, 1.06) 1.00 (0.95, 1.05) 1.02 (0.98, 1.06) 
Flu/pnemo hosp 1.04 (0.98, 1.11) 1.04 (0.98, 1.11) 0.96 (0.91, 1.03) 1.01 (0.96, 1.07) 
Death 1.04 (0.99, 1.10) 1.01 (0.95, 1.06) 1.01 (0.95, 1.06) 1.02 (0.97, 1.06) 
          
Hypertension         
ILI 1.02 (0.96, 1.08) 0.99 (0.94, 1.05) 0.96 (0.91, 1.02) 0.99 (0.94, 1.04) 
Flu/pnemo hosp 1.00 (0.93, 1,07) 0.97 (0.90, 1.04) 0.93 (0.87, 1.00) 0.96 (0.91, 1.02) 
Death 0.97 (0.90, 1.03) 0.96 (0.90, 1.02) 0.96 (0.90, 1.02) 0.96 (0.91, 1.01) 
          
Glomerulonep.         
ILI 1.03 (0.95, 1.13) 1.05 (0.96, 1.15) 1.02 (0.94, 1.12) 1.04 (0.96, 1.11) 
Flu/pnemo hosp 0.95 (0.85, 1.06) 0.99 (0.88, 1.11) 0.99 (0.89, 1.11) 0.98 (0.89, 1.07) 
Death 1.15 (1.03, 1.30) 1.06 (0.94, 1.19) 0.99 (0.88, 1.11) 1.06 (0.97, 1.17) 
          
Cystic Kidney         
ILI 0.96 (0.80, 1.17) 0.99 (0.82, 1.20) 1.00 (0.83, 1.21) 0.99 (0.84, 1.16) 
Flu/pnemo hosp 1.01 (0.78, 1.30) 1.00 (0.78, 1.29) 0.94 (0.73, 1.22) 0.98 (0.80, 1.22) 
Death 1.13 (0.88, 1.43) 0.93 (0.73, 1.18) 1.01 (0.80, 1.29) 1.02 (0.84, 1.24) 
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Table 18. Ratio of HRs by vintage 
 
 
 
 
 
 
 
 
 
 
 
  1998 vs. 1997 1999 vs. 1997 2001 vs. 1997 Pooled vs. 1997 
  Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
Adjusted RHR 
95% CI 
0 years         
ILI 0.99 (0.80, 1.23) 1.13 (0.90, 1.40) 0.89 (0.72, 1.10) 0.99 (0.83, 1.19) 
Flu/pnemo hosp 0.88 (0.66, 1.16) 0.98 (0.74, 1.30) 0.84 (0.64, 1.10) 0.89 (0.71, 1.13) 
Death 0.96 (0.75, 1.24) 1.01 (0.79, 1.30) 0.87 (0.68, 1.12) 0.95 (0.77, 1.17) 
          
1-2 years         
ILI 1.05 (1.00, 1.10) 0.98 (0.94, 1.03) 0.99 (0.94, 1.03) 1.00 (0.97, 1.05) 
Flu/pnemo hosp 1.05 (0.98, 1.11) 1.01 (0.95, 1.07) 0.98 (0.93, 1.05) 1.01 (0.96, 1.06) 
Death 0.98 (0.93, 1.04) 0.95 (0.90, 1.07) 0.97 (0.92, 1.02) 0.97 (0.92, 1.01) 
          
3-4 years         
ILI 1.03 (0.96, 1.09) 1.03 (0.97, 1.09) 0.99 (0.93, 1.05) 1.01 (0.96, 1.07) 
Flu/pnemo hosp 1.00 (0.92, 1.08) 1.05 (0.97, 1.14) 0.95 (0.88, 1.02) 1.00 (0.93, 1.06) 
Death 1.07 (0.99, 1.14) 1.04 (0.97, 1.12) 1.01 (0.95, 1.09) 1.04 (0.98, 1.10) 
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VI. RESULTS: “ASSESSING HOSPITALIZATION AND SKILLED NURSING 
CARE AS TIME-VARYING PREDICTORS OF INFLUENZA 
VACCINATION: AN EXAMPLE OF THE HEALTHY-USER EFFECT” 
 
 
 Introduction A.
  
Patients who receive prevention health care, such as preventive medications, 
screening tests, and vaccinations, have been shown to be in overall better health 
and more likely to engage in other healthy behaviors.1,2 This situation has the 
potential to exaggerate the benefits of the intervention under study, resulting in 
what is called the healthy-user bias.3 The healthy user bias has been suspected 
in studies of preventive medications such as hormone replacement therapy and 
cardiovascular disease,4 and with statin therapy and several disease outcomes.5-
7  Alternatively, it has been suggested in studies of influenza vaccine 
effectiveness in the elderly, that patients who are not vaccinated have a lower 
functional status.8 It appears to be difficult to adequately control for this bias 
using typical healthcare (e.g., claims) data. 
 Patients that are hospitalized or have skilled nursing care may represent 
the very extreme of the functional status continuum (i.e. they are very sick and 
more likely to die) and preventive medications and vaccinations are less likely to 
be administered to patients near death.9,10 ESRD patients are at particularly high 
risk of hospitalization, due to an increased risk of infection and cardiovascular 
disease, as well as a high prevalence of comorbidities (e.g., diabetes). Yearly, 
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inactivated influenza vaccination is recommended for this high-risk population by 
the Advisory Committee on Immunization Practices; however few studies have 
described who gets the vaccine each year, or if the vaccinated population has 
underlying characteristics that predispose them to have better health outcomes. 
Understanding who is vaccinated can better elucidate characteristics that differ 
between the vaccinated and unvaccinated populations that must be taken into 
account in studies of vaccine effectiveness (i.e. confounding variables).   
This study aimed to describe the vaccinated population within patients on 
hemodialysis and to assess if characteristics associated with vaccination 
changed over time. Specifically, we assessed how hospitalization and skilled 
nursing care were related to vaccination. We hypothesized that people with many 
hospital days or skilled nursing days each month would be less likely to be 
vaccinated, suggesting that time-varying measures of hospitalization and skilled 
nursing care may be a way of accounting for the healthy user bias in 
administrative claims data. 
 Methods B.
 
Study Population 
We used Medicare claims obtained from the United States Renal Data 
System (USRDS). The USRDS is a population-based, national system that 
collects information on all patients with ESRD in the US. Detailed health claims 
are captured for all patients with Medicare as a primary payer status (no health 
maintenance organization or Medicare as a secondary payer).  Information 
collected includes physician services, ICD-9-CM codes assigned to 
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hospitalizations and outpatient care, information on routine dialysis care and 
immunization use.  
Yearly cohorts were created for each influenza season from 1999-2005. 
To limit outcome misclassification, we used years before it was common to 
obtain influenza vaccine in the community, such as grocery stores and 
pharmacies. Our cohorts consisted of all adult, ESRD patients with Medicare as 
a primary payer and continuous hemodialysis use when follow-up began on 
September 1 of each year. Each yearly cohort consisted of patients who had 
initiated dialysis prior to October 1 of the preceding year. An eight month window 
from January 1 – August 31 prior to the start of follow-up of each year was used 
to identify insurance status and comorbidities for the patients in that cohort. 
Patients were required to be on continuous hemodialysis for 3 months prior to the 
start of follow-up.  For example, the cohort identified for the 1999 season would 
have initiated dialysis prior to October 1, 1998 and would have had Medicare as 
a primary payer from January 1 – August 31, 1999 and used continuous 
hemodialysis from June 1 – August 31. Hospital days, skilled nursing days and 
vaccination status were assessed beginning on September 1 of each year. We 
performed an analysis of time to vaccination where cohort members were 
followed each year until they experienced a vaccination event, death, kidney 
transplant, loss-to-follow up or administrative censoring on December 31 of that 
year, whichever came first. 
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Hospitalization, Skilled Nursing Care and Vaccination Status 
Hospitalization and skilled nursing facility admission and discharge dates 
were assessed using the Part A – Hospitalization Medicare claims.  
To identify influenza vaccinations, Medicare Part A hospital/outpatient files 
and Part B physician/supplier files were searched for Current Procedural 
Terminology codes 90724, 90656, 90658-60, HCPCS codes G0008 and G8482, 
and the ICD-9-CM procedure code 99.52. 
Time-fixed Covariates 
Time-fixed covariates were assessed to determine their effect on 
vaccination. The Centers for Medicare and Medicaid Services form 2827, the 
Medical Evidence Form, was used to ascertain age, race, gender, first service 
date with ESRD, and cause of kidney failure. The eight month window from 
January 1 to August 31 was searched for the following comorbidities in both Part 
A and Part B claims as identified in Liu et al.11: atherosclerotic heart disease, 
congestive heart failure, cerebrovascular accident/transient ischemic attack, 
peripheral vascular disease, other cardiac, chronic obstructive pulmonary 
disease, gastrointestinal bleeding, liver disease, dysrhythmia, cancer, and 
diabetes. Comorbidities were modeled as individual dichotomous variables in the 
final models. Adherence to dialysis was calculated using the sum of the number 
of dialysis sessions over the eight month baseline period:  patients were 
considered adherent if they had 95 sessions or more.  Patients with no recorded 
dialysis sessions over the eight month period were dropped from the analysis. 
We also included the number of hospital days over the baseline period and 
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controlled for an ad-hoc selection of potential frailty markers including oxygen 
use and use of mobility aids. Use of mobility aids were ascertained by searching 
Part A and Part B claims for HCPCS equipment codes for wheelchairs, walkers, 
canes, and assisted bathroom equipment during the baseline period (Table 9).  
Statistical Analysis 
For time-fixed covariates, we used Cox proportional hazards models to 
estimate hazard ratios12 comparing baseline characteristics with vaccination 
status. For time-varying covariates including hospitalization and skilled nursing 
care, we used separate proportional hazards models to estimate hazard ratios of 
vaccination for each exposure. We counted the number of hospital or skilled 
nursing days the patient had in the prior 30 days. These time-varying variables 
were updated each week; however, vaccination status was measured on a 
continuous (daily) scale. We fit the time-varying models by categorizing 
hospitalization and skilled nursing days into temporary (1 day), short (2-3 days), 
medium (4-14 days), medium-long (15-25 days), and long stays (26-30 days). 
We controlled for age at the start of follow-up, race, sex, cause of ESRD, 
length of time with ESRD (vintage), adherence to dialysis, number of mobility 
aids, ESRD network, baseline oxygen use, total baseline hospital days and 
comorbidities in all analyses. Continuous variables entered models assuming a 
log-linear association with vaccination. Analyses were conducted using SAS 9.2 
(Cary, NC), using Efron’s method for tied event times.13 This study was 
determined to be exempt from full review by the Institutional Review Board at the 
University of North Carolina at Chapel Hill.  
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 Results C.
There were more than 100,000 patients in the cohort for each year. 
Vaccination coverage increased from 47% to 60% over the study years. Whites 
had higher coverage than blacks and this difference increased throughout the 
study period (Table 19). In years when there was not a vaccine shortage, ~75% 
of vaccine doses were administered by the end of October. In the 2000, 2001, 
and 2004 seasons most doses were not given until November. (Figure 4).  
In the multivariable Cox proportional hazard models adjusting for time-fixed 
covariates, blacks and other races were less likely to be vaccinated, as well as 
patients with greater than a 5-day hospital stay during the baseline period. 
Patients on dialysis for 10 years or more were generally less likely to be 
vaccinated, although this was a small group and thus the estimates were 
imprecise. Older patients and patients with a high level of dialysis adherence 
were more likely to be vaccinated (Table 20). Most comorbidities did not strongly 
predict vaccination status (Table 21).  These differences persisted throughout the 
study period.  
Patients with any length of hospital stay were less likely to be vaccinated, 
however the association was stronger in patients with longer stays (15-25 days: 
HR =0.64 (95% CI: 0.62, 0.65); 26-30 days: HR =0.40 (0.38, 0.42)), suggesting 
that recently hospitalized patients were much less likely to be vaccinated than 
those not in the hospital (Table 22 and Figure 5). The estimates were similar for 
patients with any length of skilled nursing care stay of more than 1 day; these 
patients were also less likely to be vaccinated (26-30 days HR = 0.66 (0.64, 
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0.69)). However, we found only a weak effect for patients with 1 day of skilled 
nursing care (HR = 0.95 (0.86, 1.04)) (Table 22 and Figure 6).  
 Discussion D.
 
In this population-based study of high-risk patients with ESRD, we found 
that patients with a recent, long-term hospital or skilled nursing facility stay were 
much less likely to receive an influenza vaccination. The strength of the 
association for long-term stays for both variables was similar each influenza 
season during the 7-year study period. Elective hospitalizations were most likely 
represented by short stays. Patients with stays of 2-3 hospital days were most 
similar to those with no hospitalizations, indicating that perhaps physicians were 
less likely to have time to provide vaccination for those with a stay of only 1 day, 
and less likely to vaccinate if the patient was sick enough to require a longer 
stay. A surprising finding was that patients with only 1 day of skilled nursing care 
were not less likely to be vaccinated than patients with no skilled nursing care. 
The reasons for requiring skilled nursing care for only 1 day are unclear, but it 
may indicate an additional encounter with the healthcare system.  
In a study based on medical record review, Jackson et al. also found that 
patients with poor functional status are less likely to be vaccinated.8 They found 
that adjusting for variables such as dementia, assistance bathing, assistance 
ambulating, and living in a non-home setting reduced the amount of bias present 
in estimates of vaccine effectiveness. These variables, however, are generally 
not present in administrative claims data and therefore vaccine effectiveness 
studies that adjust for frailty have been limited to small studies using chart 
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review. We found similar strengths of associations for vaccination status as 
Jackson’s functional status variables, by using recent hospitalization or skilled 
nursing care in a time-varying manner.  
It is possible that patients got vaccinated during their hospital stay without 
the hospital billing Medicare for the influenza vaccine, which provides an 
alternative explanation for the monotonic decline in vaccination rates with 
increasing number of hospital days above 1 day. However, data from the hospital 
discharge summaries from Healthcare Cost and Utilization Project indicate that 
hospitals rarely gave influenza vaccinations until 2004, when vaccinations began 
to increase.14 This failure to offer influenza vaccine to hospitalized patients has 
recently been resolved – as of January 2012, the Centers for Medicare & 
Medicaid Services requires that all persons over the age of 6 months who are 
hospitalized be offered the influenza vaccine if discharged during the influenza 
season. While studies using recent data would need to take this into account, we 
do not think that the vaccination rate in the hospital was high enough during our 
study period to fully explain the results observed.  
Often in studies using administrative claims, the presence of comorbidities 
are used to characterize the health status of each patient. We found most 
comorbidities were not strongly associated with vaccination status, indicating that 
using these variables may not adequately capture the healthy user effect. In fact, 
adjustment for comorbidities in a study estimating influenza vaccine effectiveness 
resulted in a more biased estimate in the presence of strong unmeasured 
confounding.8  In addition, most comorbidities are assessed over a period at 
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baseline (8 months in our study). Therefore, having a claim for an illness at 
baseline would not capture acute illness, which may be a better proxy of severe 
frailty. Finally, it has been suggested that using ICD-9-CM comorbidity codes 
from administrative data may lack the sensitivity for identifying these illnesses, 
which can result in substantial residual confounding.15,16  
We found persistent demographic disparities in who received the vaccine 
each year. African Americans and other races consistently were less likely to be 
vaccinated. This disparity has been documented in the dialysis population,17 
adults with high risk conditions18, and the general Medicare population.19  
Explanations for this difference include varying rates of provider 
recommendations and fear of getting sick/side effects from the vaccine.20  
There were two additional time-fixed variables that could potentially be 
variables to adjust for healthy-user bias in vaccine effectiveness studies. Patients 
who were more adherent to their dialysis regimens were more likely to be 
vaccinated, while patients with a long vintage, and who are presumably sicker 
were less likely to be vaccinated. If these variables were left unadjusted, both 
would make the vaccine look more protective in studies of vaccine effectiveness. 
In comparison, age is an indicator of confounding by indication. We found that 
the oldest age group was more likely to be vaccinated, which was the age 
indication for influenza vaccine during the years studied.  
Our study may have been subject to some outcome misclassification.  As 
with any study on influenza vaccination, it is possible that patients could have 
obtained the vaccine from a non-medical establishment and paid out-of-pocket. 
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In this case, there would not be a Medicare claim for vaccination and we could 
not have determined that they were vaccinated. We chose to examine years prior 
to the popularization of obtaining vaccine in groceries and pharmacies, although 
the later years in our study may have been affected by this trend. Additionally, 
because influenza vaccine is covered by Medicare for our study population and 
patients on dialysis usually have healthcare encounters 2-3 times per week, we 
expect that the number of people who paid out of pocket would be low.  
In summary, this analysis suggests that patients with a recent, long-term 
hospitalization or skilled nursing facility stay were much less likely to undergo the 
preventive health measure of influenza vaccination. Further work on 
understanding how these variables could be used to control the healthy user bias 
in effectiveness studies of preventive medications is needed. 
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 Tables and Figures E.
 
Table 19. Description of yearly cohorts 
Year 1999 2000 2001 2002 2003 2004 2005 
        
 N=118,659 N=123,241 N=127,954 N=131,179 N=133,154 N=128,847 N=122,671 
 % % % % % % % 
Mean age (SD) 62.0 (14.6) 62.3 (14.5) 62.7 (14.5) 63.0 (14.4) 63.5 (14.4) 63.8 (14.3) 64.1 (14.3) 
Male sex 51.9 52.2 52.4 52.8 52.9 53.0 53.2 
Race        
   White 51.6 52.0 52.8 53.3 53.9 54.0 54.4 
   Black 43.3 42.8 41.9 41.3 40.6 40.4 39.9 
   Other 5.1 5.2 5.3 5.4 5.5 5.6 5.7 
Cause of ESRD        
   Diabetes 40.3 41.2 42.3 43.6 44.3 45.4 46.3 
   Hypertension 30.9 30.5 30.2 29.9 29.9 29.9 29.8 
   Glomerulonephritis 12.8 12.4 11.9 11.3 10.7 10.1 9.7 
   Cystic Kidney 2.9 2.8 2.7 2.5 2.4 2.3 2.1 
   Other 13.2 13.0 12.9 12.7 12.7 12.3 12.1 
Vintage        
   0 years 2.1 2.0 2.0 1.9 1.9 2.0 1.9 
   1-2 years 40.8 40.5 40.1 39.7 39.2 38.6 38.0 
   3-4 years 25.2 25.2 25.6 26.0 25.9 26.0 26.0 
   5-9 years 23.1 23.4 23.4 23.4 24.0 24.3 24.6 
   10+ 8.8 8.9 9.0 9.0 9.1 9.2 9.5 
Mean hospital days (SD) 9.9 (17.3) 9.8 (17.3) 10.3 (17.9) 10.7 (18.3) 10.8 (18.4) 11.3 (18.8) 12.0 (19.4) 
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Table 20. Adjusted* hazard ratios for time fixed variables and vaccination status by year 
    * Adjusted for all other variables in the table, ESRD network, and baseline comorbidities 
 
Year 1999 2000 2001 2002 2003 2004 2005 Pooled 
         
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
% Vaccinated 47.6 46.9 48.1 56.8 58.3 58.3 61.0  
Age         
   18-44 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
   45-64 1.13 (1.10, 1.16) 1.16 (1.13,1.19) 1.18 (1.15, 1.22) 1.16 (1.13, 1.19) 1.17 (1.14, 1.20) 1.12 (1.10, 1.16) 1.10 (1.07, 1.13) 1.15 (1.13, 1.16) 
   65-74 1.25 (1.22, 1.29) 1.28 (1.24,1.32) 1.29 (1.25, 1.33) 1.24 (1.21, 1.28) 1.23 (1.19, 1.26) 1.17 (1.14, 1.20) 1.16 (1.13, 1.20) 1.23 (1.19, 1.27) 
   75+ 1.25 (1.21, 1.29) 1.31 (1.27,1.35) 1.34 (1.30, 1.39) 1.26 (1.22, 1.29) 1.24 (1.20, 1.27) 1.22 (1.19, 1.26) 1.18 (1.15, 1.22) 1.25 (1.24, 1.28) 
Male Sex 1.08 (1.06, 1.10) 1.06 (1.04,1.08) 1.06 (1.04, 1.08) 1.05 (1.04, 1.07) 1.06 (1.04, 1.07) 1.04 (1.02, 1.05) 1.04 (1.02, 1.05) 1.05 (1.05, 1.06) 
Race         
  White 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
  Black 0.75 (0.74, 0.77) 0.72 (0.71,0.74) 0.73 (0.72, 0.74) 0.77 (0.76, 0.79) 0.79 (0.78, 0.80) 0.78 (0.77, 0.79) 0.80 (0.79, 0.82) 0.77 (0.76, 0.77) 
  Other 0.88 (0.84, 0.91) 0.80 (0.77,0.83) 0.83 (0.80, 0.87) 0.87 (0.84, 0.90) 0.93 (0.90, 0.97) 0.81 (0.78, 0.84) 0.87 (0.84, 0.90) 0.86 (0.82, 0.89) 
Cause         
  Diabetes 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
  Hypertension 0.97 (0.94, 0.99) 1.00 (0.98, 1.03) 1.01 (0.98, 1.03) 0.99 (0.97, 1.01) 0.98 (0.96, 1.00) 0.99 (0.97, 1.01) 0.98 (0.96, 1.00) 0.99 (0.98, 1.00) 
  Glomeruloneph.  1.00 (0.97, 1.03) 1.00 (0.97, 1.04) 1.03 (1.00, 1.07) 1.01 (0.98, 1.04) 0.99 (0.97, 1.02) 0.99 (0.96, 1.02) 0.98 (0.95, 1.01) 1.00 (0.99, 1.01) 
  Cystic Kidney 1.05 (1.00, 1.10) 1.07 (1.02, 1.13) 1.04 (0.99, 1.10) 1.01 (0.97, 1.06) 0.99 (0.95, 1.04) 1.01 (0.96, 1.06) 0.99 (0.94, 1.05) 1.02 (1.00, 1.04) 
  Other 0.98 (0.95,1.01) 1.00 (0.97, 1.03) 1.01 (0.98, 1.04) 0.97 (0.95, 1.00) 0.96 (0.94, 0.99) 0.97 (0.95, 1.00) 0.97 (0.94, 0.99) 0.98 (0.97, 0.99) 
Mobility aids         
   None 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
  1 aid 1.06 (1.02, 1.10) 1.05 (1.02, 1.09) 1.04 (1.00, 1.07) 1.06 (1.03, 1.09) 1.06 (1.03, 1.09) 1.04 (1.02, 1.07) 1.02 (0.99, 1.05) 1.05 (1.04, 1.06) 
  2+ aids 1.33 (1.13, 1.55) 1.01 (0.84, 1.21) 1.27 (1.10, 1.47) 1.13 (0.98, 1.29) 1.14 (1.03, 1.26) 1.03 (0.94, 1.12) 1.02 (0.94, 1.10) 1.09 (1.05, 1.14) 
Vintage         
   0 years 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
   1-2 years 0.97 (0.92, 1.03) 1.03 (0.97, 1.09) 0.99 (0.93, 1.05) 0.98 (0.93, 1.03) 1.01 (0.96, 1.06) 1.07 (1.01, 1.12) 0.97 (0.92, 1.02) 1.00 (0.98, 1.02) 
   3-4 years 0.99 (0.93, 1.05) 1.03 (0.97, 1.10) 0.99 (0.94, 1.05) 0.98 (0.93, 1.03) 0.94 (0.90, 1.00) 1.09 (1.03, 1.15) 1.02 (0.97, 1.08) 1.00 (0.98, 1.02) 
   5-9 years 0.97 (0.91, 1.03) 0.99 (0.93, 1.05) 0.96 (0.90, 1.02) 0.97 (0.92, 1.02) 1.02 (0.97, 1.07) 0.95 (0.90, 1.01) 0.97 (0.91, 1.02) 0.98 (0.96, 1.00) 
   10+ 0.80 (0.75, 0.86) 0.93 (0.87, 1.00) 0.94 (0.87, 1.01) 0.90 (0.84, 0.96) 0.93 (0.87, 0.99) 0.94 (0.88, 1.00) 0.90 (0.85, 0.96) 0.91 (0.88, 0.93) 
Adherence 1.42 (1.38, 1.46) 1.29 (1.25, 1.32) 1.47 (1.43, 1.51) 1.57 (1.53, 1.61) 1.51 (1.47, 1.55) 1.56 (1.52, 1.60) 1.58 (1.54, 1.63) 1.48 (1.47, 1.50) 
Oxygen use 1.02 (0.99, 1.06) 1.05 (1.01, 1.09) 0.98 (0.94, 1.03) 1.01 (0.98, 1.05) 1.06 (1.02, 1.09) 1.11 (1.08, 1.15) 1.05 (1.02, 1.08) 1.05 (1.03, 1.06) 
No. hospital days         
   None 1.00 1.00 1.00 1.00 1.00 1.00 1.00  
   1-5 days 0.99 (0.96, 1.01) 0.97 (0.94, 0.99) 0.99 (0.96, 1.01) 0.98 (0.96, 1.00) 0.95 (0.93, 0.97) 1.00 (0.98, 1.02) 0.98 (0.96, 1.00) 0.98 (0.97, 0.99) 
   6-30 days 0.90 (0.88, 0.92) 0.89 (0.87, 0.91) 0.90 (0.88, 0.92) 0.89 (0.87, 0.90) 0.90 (0.88, 0.91) 0.93 (0.91, 0.94) 0.91 (0.89, 0.93) 0.90 (0.90, 0.91) 
   31+ 0.77 (0.75, 0.80) 0.76 (0.74, 0.79) 0.78 (0.76, 0.81) 0.74 (0.72, 0.77) 0.78 (0.76, 0.81) 0.81 (0.79, 0.83) 0.80 (0.78, 0.82) 0.78 (0.77, 0.79) 
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Table 21. Adjusted* association between comorbidities and vaccination status by year 
* Adjusted for all other comorbidities in the table, ESRD network, and all other time-fixed covariates.  AHD = Atherosclerotic heart disease, CHF = 
Congestive heart failure, PVD = Peripheral vascular disease, CD = cardiac disease, COPD = Chronic obstructive pulmonary disease, GI = 
Gastrointestinal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1999 2000 2001 2002 2003 2004 2005 Pooled 
         
 HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
         
AHD 1.04 (1.02, 1.06) 1.06 (1.04, 1.08) 1.04 (1.02, 1.06) 1.04 (1.02, 1.06) 1.05 (1.03, 1.07) 1.03 (1.02, 1.05) 1.04 (1.03, 1.06) 1.04 (1.03, 1.05) 
CHF 0.96 (0.94, 0.98) 0.98 (0.96, 1.00) 0.96 (0.94, 0.98) 0.94 (0.92, 0.96) 0.96 (0.94, 0.97) 0.95 (0.94, 0.97) 0.96 (0.94, 0.97) 0.96 (0.95, 0.97) 
TIA 0.95 (0.92, 0.97) 0.94 (0.91, 0.96) 0.94 (0.92, 0.96) 0.94 (0.92, 0.96) 0.93 (0.91, 0.95) 0.95 (0.93, 0.97) 0.92 (0.90, 0.94) 0.94 (0.93, 0.95) 
PVD 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 0.99 (0.97, 1.01) 0.97 (0.96, 0.99) 0.97 (0.96, 0.99) 0.97 (0.96, 0.99) 0.96 (0.94, 0.97) 0.98 (0.97, 0.98) 
Other CD 1.02 (0.99, 1.04) 1.00 (0.98, 1.02) 1.01 (0.99, 1.03) 0.99 (0.97, 1.00) 1.02 (1.01, 1.04) 1.02 (1.00, 1.04) 1.00 (0.98, 1.01) 1.01 (1.00, 1.01) 
Liver disease 0.88 (0.85, 0.91) 0.95 (0.91, 0.99) 0.93 (0.89, 0.97) 0.95 (0.92, 0.98) 1.00 (0.97, 1.03) 1.04 (1.00, 1.07) 1.03 (1.00, 1.06) 0.97 (0.96, 0.99) 
COPD 1.00 (0.97, 1.02) 1.00 (0.98, 1.03) 1.00 (0.98, 1.02) 1.01 (0.99, 1.03) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02) 0.99 (0.97, 1.01) 1.00 (0.99, 1.01) 
GI bleed 0.99 (0.96, 1.02) 1.03 (1.00, 1.06) 0.98 (0.95, 1.01) 0.98 (0.95, 1.00) 0.94 (0.91, 0.96) 1.00 (0.97, 1.02) 0.95 (0.93, 0.98) 0.98 (0.97, 0.99) 
Dysrhythmia 0.99 (0.97, 1.02) 1.00 (0.98, 1.03) 1.00 (0.98, 1.02) 1.00 (0.98, 1.02) 0.98 (0.96, 1.00) 1.01 (0.99, 1.03) 0.99 (0.97, 1.01) 1.00 (0.99, 1.00) 
Cancer 1.03 (0.99, 1.06) 1.04 (1.00, 1.07) 1.05 (1.02, 1.08) 1.02 (0.99, 1.05) 1.02 (0.99, 1.05) 1.02 (0.99, 1.05) 1.02 (1.00, 1.05) 1.03 (1.02, 1.04) 
Diabetes 1.02 (1.00, 1.05) 1.04 (1.01, 1.06) 1.04 (1.02, 1.07) 1.02 (1.00, 1.04) 1.01 (0.99, 1.03) 0.99 (0.97, 1.03) 0.98 (0.96, 1.00) 1.01 (1.00, 1.02) 
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Table 22. Adjusted* assessment of hospitalization and skilled nursing care as time-varying predictors of 
vaccination 
Year 1999 2000 2001 2002 2003 2004 2005 Pooled 
         
 Adjusted HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
         
Hospital days         
  None 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  1 day 0.91 (0.83, 1.01) 0.80 (0.73, 0.87) 0.83 (0.76, 0.91) 0.82 (0.75, 0.89) 0.84 (0.77, 0.91) 0.79 (0.72, 0.86) 0.85 (0.79, 0.93) 0.83 (0.81, 0.86) 
  2-3 days 0.95 (0.91, 1.00) 0.96 (0.92, 1.00) 0.95 (0.91, 0.99) 0.93 (0.89, 0.97) 0.91 (0.88, 0.95) 0.90 (0.87, 0.94) 0.95 (0.91, 0.98) 0.93 (0.92, 0.95) 
  4-14 days 0.84 (0.81, 0.87) 0.84 (0.81, 0.87) 0.79 (0.77, 0.82) 0.87 (0.84, 0.89) 0.86 (0.84, 0.88) 0.85 (0.83, 0.88) 0.83 (0.81, 0.85) 0.84 (0.83, 0.85) 
  15-25 days 0.59 (0.54, 0.64) 0.61 (0.56, 0.66) 0.62 (0.58, 0.67) 0.68 (0.64, 0.73) 0.64 (0.60, 0.68) 0.66 (0.62, 0.70) 0.62 (0.58, 0.66) 0.64 (0.62, 0.65) 
  26-30 days 0.35 (0.30, 0.41) 0.31 (0.26, 0.37) 0.30 (0.26, 0.35) 0.41 (0.36, 0.46) 0.42 (0.37, 0.47) 0.47 (0.42, 0.53) 0.42 (0.38, 0.47) 0.40 (0.38, 0.42) 
         
SNF days         
  None 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
  1 day 0.62 (0.40, 0.96) 0.87 (0.67, 1.13) 0.52 (0.38, 0.72) 0.96 (0.78, 1.19) 1.07 (0.83, 1.38) 1.23 (1.00, 1.52) 0.98 (0.80, 1.19) 0.95 (0.86, 1.04) 
  2-3 days 0.58 (0.42, 0.80) 0.67 (0.53, 0.83) 0.67 (0.55, 0.82) 0.58 (0.48, 0.70) 0.62 (0.52, 0.73) 0.72 (0.59, 0.88) 0.67 (0.56, 0.80) 0.65 (0.60, 0.70) 
  4-14 days 0.64 (0.58, 0.71) 0.61 (0.55, 0.67) 0.64 (0.58, 0.70) 0.66 (0.60, 0.71) 0.67 (0.62, 0.72) 0.71 (0.66, 0.76) 0.65 (0.61, 0.70) 0.66 (0.64, 0.68) 
  15-25 days 0.63 (0.56, 0.72) 0.55 (0.48, 0.62) 0.61 (0.54, 0.67) 0.66 (0.60, 0.72) 0.63 (0.58, 0.69) 0.68 (0.63, 0.74) 0.65 (0.60, 0.70) 0.64 (0.62, 0.66) 
  26-30 days 0.68 (0.59, 0.78) 0.59 (0.52, 0.67) 0.55 (0.49, 0.62) 0.67 (0.61, 0.74) 0.61 (0.56, 0.67) 0.72 (0.66, 0.78) 0.72 (0.67, 0.78) 0.66 (0.64, 0.69) 
         
*Adjusted for age, race, sex, cause of ESRD, vintage, adherence, mobility aids, ESRD network, oxygen use, baseline hospital days and 
comorbidities 
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Figure 4. Distribution of vaccination administration by month and year 
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Figure 5. Cumulative incidence of vaccination by hospital days and year 
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Figure 6. Cumulative incidence of vaccination by skilled nursing days and 
year 
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VII. RESULTS: “ESTIMATING INFLUENZA VACCINE EFFECTIVENESS 
USING A MARGINAL STRUCTURAL MODEL TO CONTROL FOR THE 
HEALTHY USER BIAS” 
 
 Introduction A.
 
Administration of trivalent, inactivated seasonal influenza vaccine to patients 
on hemodialysis has become routine practice at most dialysis clinics over the 
past two decades. Although influenza vaccine has been recommended by the 
Advisory Committee on Immunization Practices for all ESRD patients for over 40 
years,1 it is currently unclear if the vaccine has an effect on clinical health 
outcomes such as mortality.2 To date, there have been only two studies in this 
population that estimated vaccine effectiveness (VE) that produced conflicting 
results: one study reported VE for influenza/pneumonia hospitalizations to be 12-
14% and 25% for all-cause mortality,3 while a more recent study reported no 
effect.4 Recent studies in the non-dialysis, elderly population have suggested that 
large VE effects (up to 50% reduction of all-cause mortality in some studies5-7) 
obtained from standard epidemiologic studies may be due to confounding by 
uncontrolled variables leading to the healthy user bias, and the true vaccine 
effect may be smaller than previously thought.8-12 It has been suggested that 
functional status/frailty is the primary cause of this confounding.8 Patients who 
are currently hospitalized or are receiving skilled nursing care are likely at a 
greater risk of death. Because preventive medications are less likely to be 
99 
 
administered to patients near death,13 hospitalization and skilled nursing care 
may also represent strong predictors of vaccination. Changes in frailty occur over 
time and likely have acute effects on death, and should therefore be accounted 
for in a time-varying manner. It is also likely that frailty, marked by hospitalization 
or skilled nursing care is affected by prior vaccination during the influenza 
season.14 Therefore, frailty is likely a time-varying confounder since it predicts 
vaccination status, is affected by prior vaccination status, and is clearly an 
independent risk factor for mortality. In the situation of time-varying confounding 
that is affected by prior exposure, marginal structural models have been 
proposed to provide an unbiased, causal estimate.15 We aimed to estimate the 
causal effect of influenza vaccination on mortality among patients on 
hemodialysis using a marginal structural model estimated with inverse probability 
of treatment weights. 
 Methods B.
 
Study Population 
Cohorts were constructed using Medicare claims obtained from the 
USRDS. The USRDS is a population-based, national system that collects 
information on all patients with ESRD in the US. While mortality information is 
collected on all patients, detailed health claims are captured only for patients who 
have Medicare as their primary payer. Health information that is collected 
includes physician services, ICD-9-CM codes assigned to hospitalizations and 
outpatient care, information on routine dialysis care and immunization use.  
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We created cohorts in two different influenza seasons that were 
dominated by the same influenza strain and matched the vaccine strain: 1999-
2000 and 2001-2002.16,17 For comparison, we also created a cohort for the 2003-
2004 season where the vaccine strain did not match the circulating virus.18 To 
limit exposure misclassification, we used years before it was common to obtain 
influenza vaccine in the community, such as grocery stores and pharmacies. Our 
cohorts consisted of all adult, ESRD patients with Medicare as a primary payer 
and continuous hemodialysis use. Each yearly cohort consisted of patients who 
had initiated dialysis prior to October 1 of the preceding year. An eight month 
window from January 1 through August 31 of each year was used to identify 
insurance status and comorbidities for the patients in that cohort. Patients were 
required to be on continuous hemodialysis for 3 months prior to the start of 
follow-up.  For example, the cohort identified for the 1999 season would have 
initiated dialysis prior to October 1, 1998 and would have had Medicare as a 
primary payer from January 1 – August 31, 1999 and used continuous 
hemodialysis from June 1 – August 31. Hospital days, skilled nursing days and 
vaccination status were assessed beginning on September 1 of each year. 
Cohort members were followed each year until they experienced death, loss-to-
follow up or administrative censoring on August 31 of the following year. 
Exposure and outcome assessment 
To identify influenza vaccinations, Medicare Part A hospital/outpatient files 
and Part B physician/supplier files were searched for CPT codes 90724, 90656, 
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90658-60, HCPCS codes G0008 and G8482, and the ICD-9-CM procedure code 
99.52. 
Deaths are reported using CMS form 2746: ESRD Death Notification. 
Dialysis providers are required to submit this form within 30 days of a patient’s 
death. Reporting of deaths is nearly complete – CMS estimates 99% of patient 
deaths are captured using this form.19   
Covariates 
Hospitalization and skilled nursing facility admission and discharge dates 
were assessed using the Medicare institutional claims. We counted the number 
of hospital and skilled nursing days in the prior 7 days and updated these 
variables at the beginning of each week.  
We also adjusted for time-fixed baseline covariates. The Centers for 
Medicare and Medicaid Services form 2827, the Medical Evidence Form, was 
used to ascertain age, race, gender, first service date with ESRD, and cause of 
kidney failure. The eight month window from January 1 to August 31 was 
searched for oxygen use and pneumococcal vaccination (CPT code=90732, 
HCPCS code=G0009), and the total number of hospital days. Adherence to 
dialysis was calculated using the sum of the number of dialysis sessions over the 
eight month baseline period:  patients were considered adherent if they had 95 
sessions or more.  Patients with no recorded dialysis sessions over the eight 
month period were dropped from the analysis. Use of mobility aids were 
ascertained by searching Part A and Part B claims for HCPCS equipment codes 
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for wheelchairs, walkers, canes, and assisted bathroom equipment during the 
baseline period (Table 9).  
Statistical Analysis 
A separate model was fit for each influenza season, where the origin was 
September 1 for each year and patients were followed until August 31 of the 
subsequent year. For the conventional analysis, we used pooled logistic models 
using week as the timescale to estimate discrete-time approximations20 of hazard 
ratios21 comparing vaccinated to unvaccinated within each year. The largest per 
week proportion of deaths was 3%, which satisfies the rare event requirement for 
the discrete-time approximation.20 Vaccination was modeled as a time-varying 
covariate, with all cohort members entering the analysis in September 1 as 
unvaccinated. Once vaccinated, patients remained in the vaccinated category 
until they experienced death, were lost to follow-up, or were censored at the end 
of that influenza year (August 31).   
The marginal structural model was estimated using inverse probability of 
treatment weights. These weights create a “pseudo-population” where each 
subject is weighted by the inverse of the probability of receiving the exposure that 
they actually did receive conditional on covariates.22 Confounders should be 
distributed equally across vaccination groups in the pseudo-population. Vaccine 
effectiveness was estimated by comparing vaccinated to unvaccinated patients 
within this unconfounded pseudo-population.  
To estimate the weights we fit a logistic model that treats each person-
week as an observation (i.e. time-varying weights were estimated for each week 
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of follow-up, from September 1 through August 31st of the following year). The 
weights were calculated from the predicted values from the pooled logistic model 
using prior time-varying confounders, baseline confounders, and prior time-
varying vaccination status as predictor variables. To ensure correct ordering of 
covariate and exposure data, we used covariate information up through the 
previous week, to predict the current week’s vaccination status.23 The 
denominator of the weights was estimated using a pooled logistic model for the 
probability of being vaccinated each week. We used all time-fixed covariates 
including number of baseline hospital days modeled using categories (0, 1-8, 9-
15, 16+ days), age modeled with a quadratic term, and indicator variables for the 
time-varying number of hospitalization and skilled nursing facility days that a 
patient had in the past 7 days. The weights were stabilized by using a pooled 
logistic model to estimate the marginal probability of being vaccinated. We used 
robust variance estimates equivalent to generalized estimated equations with an 
independent working covariance matrix.24  
To quantify bias in both the conventional and MSM estimates, we ran the 
same models during the pre-influenza period (September 1 through the day 
before the influenza season started each year). When limited to the period prior 
to the start of influenza season when vaccine effectiveness should be biologically 
negligible, we would expect the HR estimate to be close to 1 if no confounding 
were present. This method identifies if analyses remain biased even after 
adjustment or weighting.9,25 We estimated the start of each influenza season by 
using national influenza surveillance data from the Centers for Disease Control 
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and Prevention. We defined the start of the season as the midpoint of the first 
week where more than 10% of the isolates were positive for influenza.  Analyses 
were conducted using SAS 9.2 (Cary, NC). This study was determined to be 
exempt from full review by the Institutional Review Board at the University of 
North Carolina. 
 Results C.
 
There were more than 100,000 patients in each yearly cohort, from which we 
sampled 10% to run the models. Overall, 48% of patients were vaccinated in 
1999 and 2001, and 58% were vaccinated in 2003. In all years, patients who 
received the vaccine were older, more likely to be white, had fewer baseline 
hospital days, higher adherence to dialysis, and more likely to have had the 
pneumococcal vaccine than unvaccinated patients (Table 23). These 
relationships were also observed in the 10% sampled data. 
 Standard Cox regression comparing vaccinated to unvaccinated patients 
produced naive estimates of VE on mortality between 20% (14%, 25%) in 2003 
and 27% (21%, 32%) in 2001 (Table 24). Adjustment for time-fixed baseline 
covariates moved the estimate away from the null; however, including time-
varying hospitalization and skilled nursing care moved the estimate toward the 
null. The fully adjusted models produced estimates of VE ranging from 13% (6%, 
19%) in 2003 to 20% (13%, 27%) in 2001. For all years, the model estimates 
were much farther from the null in the pre-influenza period. The fully adjusted 
models produced estimates closest to the null, however these were still more 
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exaggerated than the estimates from the full season, indicating residual 
confounding.  
 The stabilized weights for both the complete follow-up and the pre-
influenza season analyses were well behaved with means of near 1 for all years 
(Table 25). There was less variation between years using the marginal structural 
model, with estimates of VE ranging from 34%  (24%, 43%) in 2003 to 40% 
(31%, 48%) in 2001 (Table 26). Estimates from the pre-influenza period analysis 
suggested that these results were also subject to residual confounding. There 
was a suggestion of modification by baseline health status (measured by 
hospitalization during the baseline period) in 1999, with a less biased effect in the 
non-hospitalized patients; however, this difference did not persist in later years 
(Table 26). 
 Discussion D.
 
We attempted to control the healthy user bias by using measurements of 
time-varying hospitalization and skilled nursing care, analyzed with standard and 
marginal structural models to account for time-varying confounding. This method 
did not appear to capture all of the differences in health status between the 
vaccinated and unvaccinated populations, and using the marginal structural 
model resulted in estimates with greater bias than conventional Cox proportional 
hazards models. The VE estimates of 34%-40% from the marginal structural 
model in all years most likely exaggerated the protective effect of the vaccine on 
mortality, as less than 10% of wintertime deaths are attributed to influenza each 
year.26,27   
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The standard Cox regression model that was adjusted for time-varying 
hospitalization and skilled nursing care produced estimates of 13% – 20%, which 
is closer to what has been seen in the general elderly population. However, even 
these estimates were likely biased as evidenced by high VE effects in the pre-
influenza period. Estimates of VE on all-cause mortality in previous studies in the 
general elderly population have ranged from 5% (1%, 8%) from a case-centered 
logistic regression model,28 to 21% (19%, 23%) from a Poisson model adjusted 
for number of prescriptions.29 Although the population on hemodialysis most 
likely has similar levels of immune-compromise as elderly individuals, caution is 
needed in directly comparing the two groups. Patients on hemodialysis are seen 
at medical facilities 2-3 times per week for dialysis treatments, therefore the 
reasons for being vaccinated may be different. 
 There are several assumptions that have to be made to interpret the 
estimate from a marginal structural model causally, namely positivity, correct 
model specification, uninformative censoring, and exchangeability.15 We believe 
that we adequately satisfied the first three assumptions. Patients were 
vaccinated within all levels of the covariates and the weights had distributions 
with mean of 1.0, suggesting that there were no positivity violations.23 Our results 
were robust to model specification and choice of the functional form of the model. 
Also, we had little loss-to-follow-up in each cohort and thus even if the censoring 
were informative it would not have strongly affected the estimates. It is doubtful, 
however, that the assumption of exchangeability was satisfied, and using IPTW 
may have amplified this bias due to unmeasured confounding.  
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This is the first study of influenza VE to our knowledge that has attempted 
to use time-varying measures of health status. While patients that are 
hospitalized or have skilled nursing care are clearly at increased risk for mortality, 
these two variables did not capture all of the differences in health status between 
vaccinated and unvaccinated patients. It is possible that there may be other 
indicators of health status in this population that may be measurable in claims 
data that could help address the residual confounding bias.  For example, recent 
use of other preventive health care services could represent proxies for important 
time-varying confounders.30 Previous research in the USRDS database has 
found that doses of erythropoiesis stimulating agents tend to be reduced in 
patients nearing death.31 This may also be true with other preventive medications 
used in this population such as intravenous vitamin D and iron administration. 
Recent missed outpatient dialysis sessions could also be used to identify patients 
in failing health. 
 Perhaps because of the potential for unmeasured confounding, there have 
been only a few studies that have fit marginal structural models using 
administrative claims data.32-36 None to our knowledge have used a negative 
control to verify the assumption of no unmeasured confounding. Two studies 
used the USRDS data: one investigated low hemoglobin levels and risk of 
hospitalization and death,37 and the other examined the effect of intravenous 
levocarnitine therapy on hospitalization.38 Either one or both of these studies 
used hospitalization, comorbid conditions, anemia treatment (intravenous iron, 
erythropoietin) vitamin D, and blood transfusions as time-dependent covariates to 
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estimate the weights. These variables could potentially be used in our models; 
however, it is questionable how prior vaccination could be related to some of 
these measures.   
 Our study may also have been subject to some exposure 
misclassification. Vaccinations that were paid for out of pocket by a patient would 
not be captured in our data. Because the influenza vaccine is covered by 
Medicare for our study population and dialysis patients have healthcare 
encounters 2-3 times per week, we expect that the number of people who paid 
out of pocket would be low. In addition, we used years before it was common to 
receive the influenza vaccine at grocery stores or pharmacies. 
 In summary, both the conventional and marginal structural models 
appeared to remain biased even after accounting for time-varying confounding, 
which likely resulted in exaggeration of the protective effect of the vaccine. Using 
the pre-influenza period as a negative control allowed us to determine if residual 
confounding was affecting our estimates. Further research is needed to identify 
time-varying, claims-based predictors of preventive health care use in the dialysis 
population. Identification of such predictors could reduce bias in studies of 
preventive health services in patients on hemodialysis.  
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Table 23. Description of study cohorts 
* V = vaccinated 
 
 
 
 
 
 
Season 1999 
Match 
11/24/1999 
2001 
Match 
1/9/2002 
2003 
Mismatch 
10/22/2003 
Vaccine match 
Start of season 
 Full cohort Sample Full cohort Sample Full Cohort Sample 
 V* Not V V Not V V Not V V Not V V Not V V Not V 
 N=56,504 N=62,155 N=5,533 N=6,260 N=61,482 N=66,472 N=6,121 N=6,595 N=77,606 N=55,548 N=7,751 N=5,519 
Variable % % % % N (%) N (%) % % N (%) N (%) % % 
             
Mean age (SD) 63.0 (14) 61.0 (15) 62.8 (14) 61.1 (15) 63.8 (14) 61.7 (15) 63.6 (14) 61.8 (15) 64.2 (14) 62.7 (15) 64.0 (14) 62.5 (15) 
Male sex 52.8 51.0 54.2 50.6 53.0 51.8 51.5 51.9 53.3 52.3 53.8 53.1 
Race             
   White (3) 56.3 47.3 57.1 48.2 57.3 48.5 57.6 47.9 57.0 49.6 57.0 49.7 
   Black (2) 38.9 47.2 38.1 46.4 37.7 45.8 37.2 46.3 37.5 44.9 37.5 45.1 
   Other (1) 4.8 5.4 4.7 5.4 5.0 5.7 5.2 5.7 5.5 5.5 5.4 5.3 
Cause of ESRD             
   Diabetes 41.2 39.4 41.1 39.2 42.9 41.8 43.5 42.4 45.3 42.9 45.8 41.9 
   Hypertension 30.2 31.4 30.1 30.7 29.7 30.7 30.2 30.6 29.3 30.7 28.5 32.1 
   Glomerulonephritis 12.5 13.0 13.5 13.2 11.8 12.0 11.4 11.4 10.6 10.9 11.0 10.5 
   Cystic Kidney 3.1 2.7 2.9 2.7 2.8 2.5 2.4 2.5 2.5 2.3 2.5 2.2 
   Other 12.8 13.5 12.4 14.2 12.7 13.1 12.5 13.1 12.2 13.3 12.3 13.4 
1 or more mobility aid  6.9 6.6 7.1 6.8 6.6 6.6 6.4 6.8 7.2 6.8 6.9 6.7 
Vintage (years)             
   0  2.1 2.0 2.5 2.2 2.0 2.0 2.0 1.9 1.9 1.8 1.8 2.0 
   1-2  41.9 39.9 41.5 40.1 41.0 39.3 41.7 39.0 40.6 37.1 40.3 37.7 
   3-4  25.8 24.6 25.5 23.1 26.3 25.0 25.6 25.0 25.1 26.9 25.5 25.7 
   5-9  22.8 23.3 22.9 24.9 22.7 24.0 22.8 25.1 23.9 24.0 24.2 24.6 
   10+ 7.3 10.2 7.6 9.8 8.1 9.8 8.0 9.0 8.4 10.1 8.2 10.0 
Adherent to dialysis 89.3 78.8 89.0 78.9 90.6 80.8 90.4 80.9 92.1 82.4 92.1 81.6 
Mean hosp. days (SD) 7.5 (14) 9.9 (18) 7.7 (14) 9.7 (18) 7.6 (14) 10.4(19) 7.5(14) 10.7(19) 8.0 (15) 11.3(20) 8.1 (15) 10.4(19) 
Oxygen Use 4.7 4.5 5.1 4.4 5.7 5.0 5.5 5.0 5.9 5.5 6.2 5.5 
Pneumococcal 
vaccination 
2.3 1.5 2.6 1.2 3.4 2.0 3.3 2.0 3.2 1.9 3.1 2.0 
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Table 24. Estimates of effect of vaccination on mortality using standard Cox regression   
 1999 2001 2003 
Model 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
 Full follow-up Pre-flu period Full follow-up Pre-flu period Full follow-up Pre-flu period 
       
Crude Cox model 0.79 (0.73, 0.85) 0.50 (0.42, 0.60) 0.73 (0.68, 0.79) 0.48 (0.41, 0.57) 0.80 (0.75, 0.86) 0.18 (0.12, 0.27) 
Baseline adjusted* Cox model 0.73 (0.67, 0.79) 0.48 (0.40, 0.57) 0.69 (0.64, 0.75) 0.46 (0.39, 0.55) 0.74 (0.69, 0.80) 0.18 (0.12, 0.28) 
Baseline + time-varying adjusted**  
Cox model 
0.84 (0.77, 0.91) 0.63 (0.52, 0.76) 0.80 (0.73, 0.87) 0.62 (0.52, 0.73) 0.87 (0.81, 0.94) 0.29 (0.19, 0.44) 
*Adjusted for age, race, cause of ESRD, vintage, adherence, mobility aids, oxygen use, pneumococcal vaccine, baseline hospital days 
**Adjusted for all baseline variables and time-varying hospitalization and skilled nursing care 
 
 
 
 
Table 25. Distribution of weights  
Year Mean (SD) Minimum Maximum 
Full Season    
1999 0.99 (0.40) 0.48 14.31 
2001 0.99 (0.39) 0.46 15.65 
2003 1.00 (0.64) 0.36 30.82 
    
Pre-flu period    
1999 1.00 (0.32) 0.47 15.17 
2001 1.00 (0.28) 0.46 15.58 
2003 1.00 (0.36) 0.46 39.86 
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Table 26. Estimates of effect of vaccination on mortality using marginal structural model* to account for time-
varying confounding affected by prior exposure  
 1999 2001 2003 
Model 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
Mortality HR 
(95% CI) 
 Full follow-up Pre-flu period Full follow-up Pre-flu period Full follow-up Pre-flu period 
       
Weighted, MSM model 0.65 (0.56, 0.75) 0.56 (0.44, 0.72) 0.60 (0.52, 0.69) 0.53 (0.44, 0.63) 0.66 (0.57, 0.76) 0.20 (0.13, 0.30) 
Weighted, MSM model by baseline 
hospitalization  
      
   No hospitalization 0.84 (0.61, 1.15) 0.80 (0.47, 1.35) 0.63 (0.49, 0.81) 0.58 (0.42, 0.80) 0.69 (0.56, 0.84) 0.25 (0.12, 0.55) 
   Hospitalized 0.57 (0.48, 0.67) 0.47 (0.38, 0.58) 0.58 (0.49, 0.69) 0.51 (0.42, 0.63) 0.64 (0.53, 0.78) 0.18 (0.11, 0.29) 
*Covariates used in denominator of weight: race, age, cause, vintage, adherence, mobility aids, oxygen use, pneumococcal vaccine, categorized 
baseline hospitalization, hospitalization and skilled nursing care in the past 7 days 
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VIII. CONCLUSIONS 
 
The results of this dissertation suggest that the healthy user bias is 
present and likely very strong in a population of patients with end-stage renal 
disease. Therefore, conventional analyses of influenza vaccine effectiveness that 
compare vaccinated patients with unvaccinated patients are likely to be biased. 
Using the period prior to influenza circulation or the “pre-influenza” period when 
the vaccine should have no effect, is a negative control that allows the 
investigator to check the amount of residual bias.  
  In Specific Aim 1, we used a natural experiment to control for the healthy 
user bias among patients on hemodialysis. We used the vaccine during a 
mismatched year as a working “placebo” and compared its effectiveness to well-
matched vaccines in subsequent years. The pooled ratio of hazard ratios 
comparing matched seasons with a placebo season resulted in a VE of 0% (95% 
CI: -3,2%) for ILI, 2% ( -2,5%) for hospitalization, and 0% (-3,3%) for death. 
Using this novel study design, we found little evidence that the well-matched 
vaccines were more effective than the mismatched vaccine for the prevention of 
ILI, influenza/pneumonia hospitalization and all-cause mortality. 
 In Specific Aim 2, we assessed two time-varying covariates – 
hospitalization and skilled nursing care in the past 30 days, as predictors of 
vaccine use. Patients with any length of hospital stay were less likely to be 
vaccinated, and this association was stronger in patients with longer stays (15-25 
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days: HR = 0.64 (95% CI: 0.62, 0.65); 26-30 days: HR = 0.40 (95% CI: 0.38, 
0.42). Patients were equally likely to be vaccinated if they received skilled 
nursing care for 1 day (HR = 0.95 (95% CI: 0.86, 1.04)), but less likely to be 
vaccinated if they had longer periods of skilled nursing care (26-30 days HR = 
0.66 (95% CI: 0.64, 0.69)). This finding supports the hypothesis that patients who 
are very sick are less likely to receive preventive care, including vaccinations. 
Because hospitalization and skilled nursing care are both associated with 
mortality, these variables could be used to adjust for confounding due to the 
healthy user bias in studies of influenza vaccine effectiveness on mortality.   
 Specific Aim 3 assessed VE for all-cause mortality by using a marginal 
structural model. This approach accounted for time-varying confounding by 
hospitalization and skilled nursing care that was affected by prior vaccination 
status. The marginal structural model remained biased even after accounting for 
these time-varying confounders, which likely resulted in exaggeration of the 
protective effect of the vaccine. It is possible that by using this method the bias 
was amplified. Additional variables that characterize health status are needed to 
obtain a more accurate estimate of VE.  
 In general, controlling for the healthy user bias using a natural experiment 
that implicitly controlled for all underlying health status and healthy behaviors 
resulted in estimates of VE for all outcomes that were close to the null. This 
suggests that the current influenza vaccine strategy may have a smaller effect on 
morbidity and mortality in the ESRD population than previously thought. While 
this work is not meant to suggest that vaccination should be discouraged, we 
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hope to spark the discussion of re-evaluating the current vaccine strategy for 
high-risk patients with end-stage renal disease.  
There are alternate strategies that are already approved and 
recommended for other populations or vaccines currently being developed or 
used in other countries. For example, adjuvants such as AS03 and MF59 can act 
as a delivery system for the vaccine virus and potentiate the immunogenic 
response.  One recent study demonstrated a significantly higher antibody 
response in patients on hemodialysis who use the AS03a adjuvant vaccine 
compared with the standard vaccine.1 A high-dose vaccine that contains three 
times the amount of virus compared with standard vaccine, also offers an 
alternative strategy.2 This vaccine is currently approved for the general elderly 
population, with no specific recommendation for high-risk patients. Finally, an 
intradermal vaccine was just licensed by the Food and Drug Administration. 
Currently this vaccine uses 40% less antigen than TIV to obtain the same 
immune response. There is potential for this route of administration to deliver 
higher doses of antigen for immunocompromised patients. 
 Strengths A.
 
There has been considerable debate in the literature regarding the 
effectiveness of influenza vaccines in the general elderly population. Various 
attempts have been made to control for the healthy user bias. This dissertation 
adds to the literature by using two novel methods to assess influenza VE in a 
high-risk population. The first method was a natural experiment. By comparing 
vaccinated patients in years when there was good vaccine match with vaccinated 
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patients in a year when there was a mismatch, we were able to inherently control 
all unmeasured health behaviors that could never be captured in an 
administrative claims dataset. The second method was a marginal structural 
model. This approach accounts for time-varying confounders affected by prior 
exposure, and allows for an estimate of VE that is unconfounded by time-varying 
health status. Neither method has been used in VE studies, and only a few 
examples of marginal structural models using administrative claims data can be 
found in the literature.3-6  
Other strengths of this work included elements of the design and analysis. 
We used a variety of years in each analysis, as VE can vary from year to year. 
We selected certain years based on criteria of each influenza season to minimize 
variation between seasons. For example, we used only seasons that were 
severe and had the same type of influenza strain predominate. Furthermore, we 
specifically used the level of vaccine match in each season to make further 
comparisons. Strengths of our analysis included using covariates that had never 
been used before to control confounding. Adherence to dialysis was an important 
predictor of influenza vaccination, and could indicate exposure to other 
preventive health care services. We also attempted to capture functional status 
by using claims for mobility assistance devices; however the relationship of this 
variable with vaccination status was unclear. Using additional variables to explain 
a patient’s underlying health status could decrease the amount of residual bias in 
the final estimate of VE. 
120 
 
The final strength of this study was using the USRDS database. This 
database captures information on all patients with ESRD in the US, thus this 
study can be considered population-based. Therefore, our sample size was very 
large – we had more than 100,000 patients for each influenza season. Although 
we selected patients based on eligibility requirements, our estimates estimated 
the population effect among all those selected (i.e. hemodialysis and Medicare 
as a primary payer). Furthermore, because we are restricting our analysis to 
patients with Medicare as a primary payer, we should capture all vaccinations, 
regardless of where they were administered (i.e. hospital, dialysis clinic, 
pharmacy). Vaccinations would only be missed if patients paid out of pocket – 
and this scenario is expected to be only a small proportion of all influenza 
vaccinations as we limited our analysis to years before it became common 
practice to offer the vaccine in settings where paying out of pocket was 
necessary, such as grocery stores.   
 Limitations B.
 
One of the major limitations of using administrative claims databases is 
the lack of information on potential confounding variables. Therefore, the 
assumption of no unmeasured confounding may not be valid. While this 
assumption is inherent in all models of observational data, it is particularly 
important when using models for causal inference, as in the case of the marginal 
structural model. Although we cannot test this assumption, using a variety of 
baseline variables, as well as time-varying confounders may be adequate for this 
population. An important variable that we may not have captured fully was 
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frailty/functional status. We attempted to capture mobility by using claims for 
wheelchairs, walkers, canes and bathroom equipment. However, we would not 
have captured long-term mobility impairments, which could likely influence a 
person’s functional status. Additionally, restricting the population to patients with 
end-stage renal disease reduces the variability in health status, as all patients 
are relatively sick because they are on dialysis.  Finally, we did not have drug 
information, which could have further helped to elucidate healthy user behaviors 
by identifying those patients who were taking preventive medications, such as 
statins.   
 Another important limitation is ascertainment of outcomes used in this 
analysis. The best outcome to use for vaccine effectiveness studies would be 
lab-confirmed influenza. This information is rarely collected however; thus we 
had to use less specific outcomes, which could dilute the effect of the vaccine 
because some of the outcomes may have been caused by infections other than 
influenza. Additionally, there may have been error in collecting and coding of 
outcomes. Particularly in Study Aim 1, the outcomes of ILI and 
influenza/pneumonia hospitalization may have been misclassified. The specificity 
for the influenza/pneumonia outcome was likely high (i.e. if the patient did not 
have a claim, they did not have the outcome), which would not bias effect 
estimates even in the presence of modest sensitivity.7 Additionally, it is likely that 
the ILI outcome was under-ascertained. Unless physicians were making their 
diagnosis in part on the basis of the patient’s vaccination status during the visit, 
this misclassification would be non-differential and the bias would be toward the 
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null. Because this outcome has only been used in one other study, further 
validation of this outcome would strengthen the results. Additionally, using a 
dataset with drug information would likely find more cases of ILI if prescription 
drug claims for antiviral prescriptions (i.e. amantadine, rimantadine, oseltamivir, 
Zanamivir) could be ascertained. 
 Future directions C.
 
This research has attempted to resolve the methodological issues 
surrounding the healthy user bias using observational data. Our results from the 
natural experiment suggest that the vaccine does not work as well as previously 
thought. Because there are several other options on the market (either 
recommended for other populations or vaccine formulations used in other 
countries) a randomized controlled trial among patients on hemodialysis may be 
warranted. Due to ethical limitations this study could not be a placebo-controlled 
trial, however, patients could be randomized to either the “newer” vaccines or the 
standard TIV dose given currently. Vaccines that could be tested include the 
high-dose vaccine, intradermal vaccine, adjuvanted vaccines (used in Europe) or 
the TIV vaccine given in multiple doses. Both serological and clinical endpoints 
would be of interest.   
Further analysis of comorbidity data and development of a method of 
ascertaining the severity of comorbidities in claims data is also needed. For 
example, it may be the case that a comordibity claim for a patient that has been 
vaccinated may indicate less severe disease and routine use of health care 
services, while the same comordibity claim in an unvaccinated patient could 
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represent severe disease, as patients who are unvaccinated are generally less 
healthy and less likely to receive routine services. Identifying patterns in codes or 
validation studies with linked databases could help to understand what certain 
comorbidity claims actually represent. This could not only assist with confounding 
control in studies of influenza vaccine effectiveness, but could also be used to 
obtain improved estimates in any health outcomes study that adjusts for 
comorbidities. 
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